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ABSTRACT 
Introduction 
Rheumatic heart disease is still the most common cause of valvular heart lesions 
requiring replacement or repair procedures worldwide. In South Africa, where there 
is an interesting mix of first and third world dynamics, factors sustaining the 
epidemic of rheumatic disease are still commonplace. The choice of appropriate 
valve procedure and prosthesis in our setting will depend on an adequate knowledge 
of short and long term outcomes of valve replacement and repair. The aim of this 
thesis was to evaluate the demographics and presentation of our rheumatic and non-
rheumatic patients and to determine if our current implantation choices could be 
validated. 
 
Methods 
A retrospective data analysis of first incidence, single aortic and mitral valve repair 
and replacement was carried out over a 16 year period (1993-2008) at the Groote 
Schuur Hospital, Cape Town, South Africa. As follow-up in indigent patients was 
not possible, overall failure was deduced from patients returning for re-operation. 
The possibility of bias due to an oblique mortality in one of the valve-type groups 
therefore needs to be considered. 
 
Results 
Of the 1,449 patients, 770 (53.1%) were rheumatic while 679 (46.9%) were non-
rheumatic. Rheumatic heart disease was significantly associated with female gender 
(p<0.0001), black and coloured racial groups (p<0.0001), informal housing 
(p<0.0001) and unemployment (p<0.0001). The non-rheumatic patients were 
significantly older with more co-morbidity factors; smoking (p=0.038), renal failure 
(p=0.005), hypertension (p<0.0001) and diabetes (p<0.0001). 
Of 1,449 valve procedures (replacement and repair), 801(55.3%) and 648(44.7%) 
were in the mitral and aortic positions respectively. There were 1210 (83.5%) valve 
replacements with mechanical valves being the most commonly implanted (60%). 
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Mitral valve repair was attempted in only 67 (8.7%) of the rheumatic patients, and 
123 (18.1%) of the non-rheumatic group (p<0.0001). 
ICU stay, hospital stay and 30-day mortality figures were significantly better 
(76.5±113 hours vs  99.3±155.1hours (p=0.048); 11.5±10.4 days vs 13.8±27.3 days 
(p=0.05); 2% vs 11% (p<0.0001) in the rheumatic group, while time to failure for 
mechanical valves was significantly earlier in this same group (4.23 vs 6.91years; 
p=0.0039) than in the non-rheumatic group as well as tissue valve failure in 9.54 
years. 
The ratio of mechanical valves presenting for reoperation was slightly higher than 
that of tissue valve recipients (p=0.055). 
 
Conclusion 
Counter-intuitively, mechanical valves which represent our current preferred choice 
for young, black, rheumatic patients are returning significantly earlier for re-
operation than tissue valves. There is an urgent need to investigate this further with 
prospective studies.  
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CHAPTER 1.  BACKGROUND 
 
 
1.1   Introduction 
 
Heart valve surgery contributes a significant proportion of cardiac surgical workload 
worldwide, especially in the developing world where rheumatic heart disease is 
common and currently the leading etiology associated with valvular heart lesions 
necessitating valve replacement (1). 
Rheumatic heart disease is the chronic sequelae of rheumatic fever, an autoimmune, 
multi-system inflammatory response following Lancefield group A streptococcus 
(GAS) pharyngitis (2). Rheumatic fever and rheumatic heart disease are very 
prevalent in developing countries of Africa, South America and Asia, although 
pockets of high prevalence are still found in some developed countries (3). South 
Africa is a unique example of both first and third world dynamics presenting an 
interesting combination of patients. 
Re-operative valve surgery has become an inevitably fast evolving discipline as the 
number of heart valve replacement surgeries continues to increase. In the past, re-
operative surgery has been associated with a considerably higher operative mortality 
than primary valve surgery. Poor preoperative left ventricular function and duration 
on cardiopulmonary bypass, but not the number of reoperations, has been correlated 
with operative mortality (4). It remains to be shown, however, if the current 
paradigm that re-operative mortality outweighs risks of implanting mechanical 
valves is unconditionally correct. 
It is important to realize that long-term outcome criteria, such as time to re-operation 
or to Major Adverse Prosthetic Events (MAPE), such as thrombo-embolism, 
infection or bleeding, offer greater predictive value of valve performance than early 
(in-hospital) assessment of morbidity and mortality. This was confirmed by Edwards 
et al. (5) who showed that early failure of valves was largely cardiac, rather than 
being valve related, suggesting that patient risk factors, rather than prosthesis choice, 
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have greater impact on short term in-hospital outcomes such as intensive care unit 
(ICU) duration or hospital stay and 30-day mortality. 
 
1.2 Epidemiology of rheumatic heart valve disease 
 
1.2.1 Developing Countries 
 
Rheumatic fever is a disease of the poor (6) and rheumatic heart disease is still 
widely prevalent in developing countries all over the world but, due to poor facilities 
for registration of cause of death, reliable statistics are difficult to obtain. In 1995, 
the World Health Organization (WHO) estimated that 12 million people were 
affected by rheumatic fever or rheumatic heart disease worldwide, resulting in 
400,000 deaths annually (7). It is also estimated that about 282,000 new cases arise 
every year (8). Unfortunately, most countries where rheumatic fever is prevalent do 
not have the financial resources nor the sophisticated medical services to treat the 
long-term sequelae of chronic valvular heart disease (Figure 1). 
Again, there is believed to be continued and unabated prevalence in the countries of 
Asia and Africa with no change in prevalence in countries like India over a 30 year 
period, similar to other developing countries (9). A developing (often a euphemism 
for poor) country is one in which the economy has remained stagnant and the 
expected benefits of rises in standards of living have not been equitably distributed. 
Unfortunately, these countries are largely in transition with increasing urbanization 
and creation of sprawling ghettos. Some are also experiencing massive migrations of 
large segments of the population into refugee camps due to war. 
 Padmavati (10), reported a prevalence of rheumatic heart disease from 15 per 1000 
in school children in Algeria to 20 per 1000 in Iran while, in other Mediterranean 
countries such as Cyprus and Egypt, there are varying reports. In other parts of 
Africa such as Ethiopia, Nigeria and Senegal a high prevalence was also recorded. 
The actual prevalence of rheumatic heart disease is not known in South Africa (11). 
However, a reported prevalence of rheumatic fever in Johannesburg among the 
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school children of Soweto in 1996 was 6.9 per 1000 children, and as high as 20 per 
1000 among those ages 12-14 year age group (12). 
Conflicting reports arise from China with some reports suggesting that rheumatic 
heart disease is still the most common cause of valvular damage leading to surgery 
as it had been 40 years ago (13). However, Cheng (14) is of the opinion that there 
has been a marked reduction of rheumatic heart disease in China as a result of 
significant improvement in living conditions, better hygiene and good nutrition. 
 
 
Figure 1: Worldwide prevalence of rheumatic heart disease (15) 
 
1.2.2 Developed Countries 
 
Pharyngeal infection, with the causative organism GAS, is more common in areas of 
overcrowding and poor socioeconomic conditions. This may explain the decline of 
cases in the developed world, for example the USA, where the incidence of 
rheumatic fever has fallen from 100 per 100,000 population at the turn of the 
century to 45-65 per 100,000 between 1935 and 1960, and still further to 2 per 
100,000 currently (9).  
Padmavati (10) compared the differences and patterns of rheumatic heart disease in 
developed and developing countries. Two studies published in the 1960s showed 
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that the presentation of rheumatic heart disease is different in developing countries. 
These studies reported an increased rate of rheumatic heart disease among 
individuals younger than 20 years (30%), symptomatic heart disease at younger age 
of onset, less interval between the onset of symptoms and symptomatic rheumatic 
fever, and severe mitral stenosis and its complications within a short duration of 
onset of disease (16) (17). Essop and Nkomo (18) also noted that in developed 
countries, valvular disease was largely degenerative whilst infectious in developing 
countries. 
Examples of the close inverse relationship between the prevalence of rheumatic 
heart disease and wealth are provided by the evidence of its diminishing incidence in 
particular ethnic groups of higher socio-economic status while it remains high in 
lower socio-economic groups in the same region. There are differences in the 
incidence of the disease, for example, between Arabs and Jews in Israel, Malaysians, 
Indians and Chinese in Singapore, Maoris and Whites in New Zealand and Bantus, 
Asians and Whites in South Africa (19). There may also be variable susceptibility to 
GAS pharyngitis possibly due to host genetic factors, explaining the observed 
differences. 
While South Africa is a first world country with regard to the diagnosis and 
treatment of heart disease, it supports a large third world population (20) with an 
extensive and varied spectrum of valvular heart disease.  
 
1.3 Epidemiology of non-rheumatic heart valve disease. 
 
Unlike rheumatic valve disease, non-rheumatic conditions affecting the heart valve 
are either congenital or acquired. Congenital conditions most often affect the aortic 
valve, for example bicuspid aortic valves, or the pulmonary valve, for example 
pulmonary stenosis. 
Infective endocarditis, myxomatous and calcific degeneration are other non- 
rheumatic lesions. Coronary artery disease leading to ischemia of the papillary 
muscles is also encountered.  
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1.4 Valve pathology 
 
1.4.1 Mitral Valve 
 
Compared to Western countries, a different clinico-pathological spectrum of 
valvular heart disease exists in developing countries with rheumatic carditis, 
infective endocarditis, myxomatous degeneration (prolapse), and calcification 
occurring amongst others. Of these, rheumatic heart disease is still the leading 
etiology associated with mitral valve disease requiring valve replacement (Figure 2). 
Reports from Shanghai, China, indicate that more than three quarters of cases (81%) 
are rheumatic in origin while restenoses after mitral commissurotomy (4%), 
congenital heart lesions (5%), endocarditis (3%), Marfans (2%) and miscellaneous 
(5%) account for the remaining (13).  
 
Figure 2: Mitral valve with stenosis and calcification (21) 
 
In mitral stenosis, when the mitral valve orifice area is <2cm2, a pressure gradient is 
created, which gradually worsens, preventing atrial blood from filling the ventricle 
during diastole and ultimately also building pressure within the left atrium leading to 
pulmonary congestion, left atrial enlargement and atrial fibrillation. When atrial 
fibrillation develops, the ‘atrial kick’ which contributes blood to the left ventricle 
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during late ventricular diastole is finally lost, leading to a precipitous decrease in 
cardiac output and congestive cardiac failure. 
In mitral regurgitation, the LV volume increases and the contractile function 
deteriorates and thus leading to dysfunctional LV and a decrease in ejection fraction. 
Regurgitant volume in mitral regurgitation causes a volume and pressure overload of 
the left atrium and eventually pulmonary overload. 
In general, the ultimate lesions caused by disease in valves produce stenosis, 
insufficiency (regurgitation or incompetence), or both. The understanding of these 
lesions is attributed largely to echocardiography as neither postmortem analysis nor 
observations made intra-operatively in a flaccid non-beating heart are able to 
appreciate the dimensions and spatial relationships of the valvular and subvalvular 
components of the mitral valve (18). 
Features of severe mitral regurgitation as seen echocardiographically in rheumatic 
fever include an increase in mitral annular diameter, mainly of the posterior annulus, 
and elongated chordae to the anterior mitral leaflet but without rupture. Remarkably, 
leaflet morphology appears normal, at least in the early stages (22). Rheumatic 
prolapse always involves the anterior leaflet whereas myxomatous prolapse has a 
predilection for the posterior leaflet. Myxomatous leaflets are thickened, voluminous 
and redundant with significant systolic bulging or billowing toward the left atrium, 
contrasting with that in rheumatic carditis (18).  
 
It is important to distinguish rheumatic mitral disease from myxomatous mitral 
disease as the long term outcomes differ. 
 Mitral valve prolapse (Barlow’s syndrome) is estimated to affect 1-3% or more of 
adults in the United States.  The basis for the changes in these valves is unknown but 
it is associated with such heritable disorders as Marfans syndrome. Most are 
asymptomatic. It has only recently been shown that asymptomatic mitral 
regurgitation is a serious disease with a 33% 5-year incidence of adverse 
cardiovascular events including death, heart failure and new atrial fibrillation (23). 
This underscores the need for these patients to have valve repair or replacement as 
soon as possible. This is evidently possible in degenerative mitral valve disease 
which is common in developed populations, but the benefits of repair are questioned 
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in rheumatically damaged valves in which the leaflets may look relatively normal on 
macroscopic examination but harbor microscopic inflammatory cell infiltration 
leading to progressive fibrosis and leaflet deformity. The overall freedom from valve 
failure in one report was only 66% after a mean follow up of 5 years (24) thought to 
be a result of the rheumatic pathology. 
 
Infective endocarditis usually leads to valvular incompetence by tearing, fraying or 
perforation of the leaflets. The subvalvar apparatus may also be affected with 
chordal and papillary muscle rupture. Very rarely, stenosis may occur from huge 
vegetations. For years, rheumatic heart disease was considered to be the major risk 
factor for development of endocarditis, accounting for between 20% to 25% in the 
1970s but dropped to 7% to 10% in the 1980s in Western countries whilst still 
responsible  for the majority of cases in developing countries. Mitral valve prolapse 
has emerged as the leading risk factor accounting for between 7-30% of native valve 
infective endocarditis in Western countries (25). 
 
1.4.2 Aortic Valve 
 
Acquired aortic stenosis results from progressive and advanced age- associated 
“wear and tear” of either previously anatomically normal aortic valves or 
congenitally diseased bicuspid valves. The prevalence of aortic stenosis, estimated at 
2% in individuals greater than 65 years of age, appears to be increasing with a rising 
average age of the population. With the decline of rheumatic fever in North 
America, rheumatic aortic stenosis now accounts for less than 10% of cases of 
acquired aortic stenosis (26). It is currently thought that degeneration, dystrophy and 
passive accumulation of hydroxyapatite mineral explain the onset of calcification. 
However, the body is able to actively regulate this, generating interest in the use of 
statins to decrease the progression of aortic stenosis (27).  
In Africa however, rheumatic aortic stenosis still produces a significant burden of 
disease. A systolic pressure gradient develops between the left ventricle and aorta, 
and in order to normalize the left ventricular wall stress, the left ventricle thickens 
producing concentric hypertrophy. This state may be maintained for several years 
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until left ventricular end diastolic pressure (LVEDP) begins to rise and diastolic 
dysfunction sets in. Although cardiac output may be sufficient at rest, it is grossly 
inadequate during exercise. When aortic stenosis is severe enough, atrial filling of 
the ventricles becomes severely impaired with the development of atrial fibrillation 
leading to heart failure. 
Rheumatic aortic regurgitation on the other hand causes an eccentric left ventricular 
hypertrophy with a compensatory increase in left ventricular end diastolic volume 
(LVEDV). The left ventricle becomes larger and more compliant with time until 
such a time when diastolic pressure begins to rise and cause symptoms. 
Other causes of aortic regurgitation include bicuspid aortic valves, which are the 
most common congenital etiology, infective endocarditis and degenerative aortic 
valve disease. Abnormalities of the ascending aorta such as may occur with long 
standing uncontrolled hypertension, Marfans syndrome and Takayasu arteritis may 
also result in aortic regurgitation. 
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CHAPTER 2.  STATUS OF HEART VALVE SURGERY WORLDWIDE 
 
Over 4 million people worldwide have received a prosthetic heart valve and it is 
estimated that about 300,000 valves are being implanted annually, which is 
projected to be 850,000 per year by 2050 because of the high incidence of rheumatic 
heart disease in developing countries and an increasing burden of degenerative valve 
disease in the ageing population (28). 
 
2.1 Design trends of valve prosthesis 
 
Ever since the first successful heart valve replacement in 1960 by Dr Dwight Harken 
using the Starr-Edwards valve (Error! Reference source not found.), mechanical 
valves have undergone much transformation from the days of the ‘ball and cage’ 
valves, the monodisc, which were either non-tilting (Table 1) or tilting (Table 2), and 
now, the bileaflet prostheses with minimal thrombogenicity and hemolysis and 
improved hemodynamic performance (Table 3). More than 70 different types of 
mechanical valves and a number f different tissue valves have been implanted 
throughout the world in the last 50 years.  
A major contribution to mechanical valves was provided by Jack Bokros who 
invented a pyrolytic carbon that he called ‘Pyrolyte’. This has been used as a 
component of mechanical valves since 1969 and over the decades has become the 
principal biomaterial for virtually all new mechanical valves. 
The most widely implanted valve so far is the ‘St. Jude Medical Bileaflet’ valve 
which has changed very little from the original type implanted in 1977. About 1.5 
million had been implanted by 2004.  Slight changes have been made in its sewing 
ring and the ‘Regent’ valve introduced in 1999 incorporates a housing design that 
significantly improves the orifice size of smaller aortic prostheses. Other valves in 
current use include the Starr-Edwards ball valve, the Carbomedics, Omniscience, 
Omnicarbon, Medtronic-Hall and the Edwards MIRA. The prosthesis most recently 
approved by the Food and Drug Administration (FDA) is the bileaflet On-X valve 
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made of pure pyrolytic carbon as opposed to its predecessors made of silicon-
alloyed pyrolytic carbon, making it stronger and tougher (29).  
While it is true that the tilting disc valves and the bileaflet valves that appeared in 
the 1970s offered hemodynamically superior aortic valve function when compared 
with the Starr-Edwards prosthesis, the SE#6120 mitral valve still provides quite 
satisfactory hemodynamic function and continues to be used, particularly in third 
world countries because of its low cost. Ikizler et al. report on a Starr-Edwards valve 
implanted 34 years ago in Turkey and still functioning even without anticoagulation 
(30). Since the first use of homografts was reported in the early 1960s, there was not 
much use of bioprostheses until the 70s and 80s when they were implanted with 
increased frequency. The main attraction of these valves was their excellent 
hemodynamic properties, low thrombogenicity and freedom from substantial 
structural degeneration during the first years of implantation (31). 
 
!
 
Figure 3: Starr-Edwards Mitral valve (32)  Figure 4: On-X Mitral valve (33) 
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Table 1: Examples of Non-Tilting Disc Valves 
Valve and year of 1st implant Year production 
ceased 
Information 
Kay-Shiley 1965  
 
1980 One of the most 
widely used mitral 
valves (1965-
1980) 
Beall-Surgistool 
1967 
 
1985 Discontinued 
because of fabric 
wear on disc apron 
Cooley-Cutter 
1971 
 
1978 Double struts 
permitted ‘full 
flow’ orifice 
Images from Gott, VL et al. (32) 
 
Table 2: Examples of Tilting Disc Valves 
Valve and year of 1st implant Year production 
ceased 
Information 
Bjork-Shiley 
1969 
 
1986 Stellite housing 
with flat Delrin 
leaflet (disc) 
Medtronic-Hall 
1977 
 
ongoing Titanium housing 
with pyrolytic 
carbon leaflet; 
with central hole  
for guide strut 
Images from Gott, VL et al. (32) 
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Table 3: Examples of Bileaflet Valves 
Valve and year of 1st implant Year production 
ceased 
Information 
St Jude (1977) 
 
 
ongoing Pyrolytic 
carbon; first all-
carbon valve in 
clinical use. 
Edwards MIRA 
(1998) 
 
ongoing Curved leaflet 
profile; 
carbofilm-
coated titanium 
alloy 
Carbomedics 
(1986) 
 
ongoing Pyrolytic 
carbon coating; 
housing can be 
rotated within 
sewing ring 
Images of St Jude and Carbomedics valves from Gott, VL et al. (32); Image of Edwards MIRA valve 
from Remadi, JP (34) 
 
Biological prostheses have been developed with the principal advantage of avoiding 
life-long anticoagulation which is the bane of mechanical valves. Despite the 
improvements in design of these glutaraldehyde treated tissue valves, with ‘new’ 
concepts such as ‘stentless’ valves, they still fall short with respect to durability, 
eventually succumbing to tissue degeneration. This resulted in a decline in their use 
to less than one third of the annual total in the late 80s (35). The legacy of the 
catastrophic early failure of the Ionescu-Shiley pericardial valve (36) due to a design 
flaw and resulting in its withdrawal in 1987, only 11 years after its introduction, may 
have been the tipping point in this decline. Today, however, there is not only a 
preference for utilization of tissue valves but, compared to their mechanical 
counterparts, these prostheses are enjoying a more rapid market expansion. This is 
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perhaps also driven by the current interest in transapical or percutaneous valves 
which are by necessity also tissue valves. Mechanical valves nevertheless remain the 
preferred prosthesis in young children where the problem of dystrophic calcification 
limits their use. 
 
2.2  Choice of prostheses 
 
Worldwide, at least 20 different valve designs are implanted annually (37). All 
clinicians should have access to a national database which reflects the range and 
performance of individual valves, thereby providing an objective and scientific basis 
on which to make the choice of valve. The United Kingdom Heart Valve Registry 
set up in 1986 has been able to show clear trends and changes in the choice of 
valves. Within a decade, it highlighted a preference for mechanical valves, although 
recent data suggest that bioprosthetic implants were on the rise. The number of 
bileaflet implants saw a significant increase with a fall of up to 73% and 76% in 
single leaflet and ball valves respectively (38). In clinical practice, the choice of a 
valve is made primarily on the basis of patient age, valve position, patient 
comorbidity and the risks and benefits of anticoagulation (4). Unfortunately, 
ultimately the choice of prosthesis model to be implanted has always been at the 
discretion of the operating surgeon and also dependent on the availability of 
different brands. 
In the mid-ni eties, about two-thirds of the approximately 210,000 patients 
worldwide undergoing valve replacement surgery annually, received mechanical 
valves (39). The use of bioprosthetic valves saw an increase from 20% to 40% in 
2000 and is believed to have reached the 50% mark currently. The majority of these 
valves, however, are implanted in the geriatric population of Europe, North America 
and Japan and less so in the developing world, where rheumatic heart disease still 
remains a huge challenge, anticoagulation is problematic, and a strong indication for 
bioprosthetic use therefore exists. The proportion of patients receiving heart valves 
in the Western world are also significantly older (peak age of 60-69) than African 
patients (peak age of 30-39) and these may have a significant impact on the choice 
of valve prosthesis (Figure 5) (40).  
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Figure 5: Age distribution of patients undergoing valve surgery at Groote Schuur Hospital  
(blue) versus that reported for the First World (red) showing a much earlier and more widely 
distributed age of onset for a developing country such as South Africa compared to the First 
World (40). 
 
There is currently a bias towards the use of mechanical prostheses in developing 
countries because of a genuine fear of reoperations due to the expected failure of 
tissue bioprostheses. The fear of a re-operation is largely the main reason for 
choosing a mechanical prosthesis because reoperations are fraught with bleeding 
from release of adhesions during re-entry.  
However, some studies have not shown any significant difference in survival 
between mechanical and bioprosthetic valves despite the known implications and 
disadvantages of both (41). 
The controversy continues as to the choice of prosthesis when reoperations are 
necessary, and perhaps more importantly in first operations with some series 
reporting higher mortality in re-replacement of a mechanical valve than with tissue 
valves (42). It can be argued that the acute and abrupt deterioration in valve function 
(eg. thrombosis) which is more common with mechanical prostheses produces a 
severely compromised patient quickly requiring more urgent intervention and 
therefore increasing the mortality. 
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Hammermeister and co-workers, reporting for the Department of Veteran Affairs 
(VA) trial which randomized 575 male patients undergoing single valve replacement 
in 13 centres between 1977 and  1982, showed significant survival at 15 years for 
patients who received a Bjork-Shiley prosthesis (79% versus 66%) in the aortic 
position compared to the Hancock porcine bioprostheses. They also showed a 
significantly increased risk of re-operation when the Hancock bioprosthesis was 
inserted in either the aortic or mitral positions (43). 
In contrast, the Edinburgh heart valve randomized trial, which was conducted 
between 1975 and 1979 with a slightly longer follow up of 20 years and reporting on 
533 patients, found no difference in patient survival. However, there was also an 
increased need for reoperation with the  Hancock bioprosthesis (44). Peterseim and 
his colleagues in a large non-randomised series of 841 patients undergoing isolated, 
first time aortic valve replacement with Carpentier-Edwards or St Jude mechanical 
prosthesis reported a similar ten year survival in each group (45). 
Other studies have however analyzed the risk factors for early and late mortality in 
reoperations with results showing no difference between mechanical and 
bioprosthetic valves (46). It is still unclear whether tissue or mechanical valves 
should be used in a background of native valve (NVE) or prosthetic valve 
endocarditis (PVE). It may be possible to prevent valve replacement by valve repair 
if adequate debridement of infected tissue can be guaranteed not to compromise the 
repair. However, ‘simple’ valve replacement still remains the procedure of choice in 
most cases of NVE (47). When the infective process involves the sewing ring or 
annulus in PVE, re-replacement surgery must be performed. Timing of surgery and 
incomplete excision of infected tissue may be partly responsible for the poor 
outcome and mortality of 30% to 80% in cases of early PVE and 20% to 40% in 
cases of late PVE (48). Infection of a bioprosthetic valve may hasten structural valve 
degeneration due to injury to the bioprosthetic leaflets. It has been suggested 
previously though that bioprosthetic valves may be less susceptible to early 
recurrent endocarditis than mechanical valves but that they may be more susceptible 
to late endocarditis due to infection of the tissue leaflets. Moon et al. recommend 
mechanical prostheses for most patients with NVE who are less than 60 years of age 
while patients older than 60 and younger patients who have limited life expectancy 
would benefit more from tissue valves (47). 
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2.3 Anticoagulation 
 
Anticoagulation is mandatory with mechanical valves as it maintains the leaflets of 
the prostheses free from thrombi as a result of altered blood flow and haemostatic 
activation caused by vessel-wall disruption during surgery or exposure of artificial 
surfaces (sutures, sewing ring, occluder and valve housing) to the circulating blood. 
This is often achieved by short-term parenteral anticoagulation with unfractionated 
heparin or low-molecular-weight heparin until a therapeutic concentration of an oral 
vitamin K antagonist, usually warfarin, is reached. 
 However, based on the socioeconomic circumstances of a significant proportion of 
these patients, anticoagulation follow-up is often impossible because of proximity to 
monitoring facilities as well as under dosage due to non-compliance (37). Ogendo 
reported in Kenyan patients with mechanical valves who attended their 
anticoagulation clinics once in 59 days that therapeutic International Normalized 
Ratio levels (INR) could be maintained only 18% of the time (49). Therefore, the 
ideal heart-valve prosthesis of choice in this setting should be a xenogeneic tissue 
valve which does not require lifelong anticoagulation because of improved blood 
flow dynamics resulting in less red cell damage and hence less clot formation. The 
disadvantage of these prostheses is their relative predictable degeneration and the 
need for re-replacement, especially in the younger patient who soon outgrows his 
valve in addition to the problem of mineralization of bioprosthetic valves in the 
young patient. Until dramatic improvements in the longevity of bioprosthetic valves 
in the younger population are therefore achieved, there remains a strong bias 
towards the deployment of mechanical prostheses in the developing world despite 
the risk of acute thromboembolic events in these patients, mainly because of the 
trepidation of inevitably having to perform a high percentage of difficult and life-
threatening valve reoperation procedures at a later time point. However, the 
avoidance of anticoagulation especially in females of child-bearing age would 
remain a reason to choose bioprosthetic valves. Unfortunately, complications arising 
from imperfect anticoagulation management are often fatal, as opposed to a possibly 
only perceived higher intra-operative mortality associated with the need for 
replacing degenerating tissue valves. Therefore, the ability of weighing re-operation 
risks in tissue-valve recipients against anti-coagulation risks in mechanical valves, 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 26 
constructed of synthetic tilting disks and hinged on a titanium stent may have 
fundamental consequences for patients needing heart valve replacement from lower 
socioeconomic circumstances. 
In clinical practice, the choice of a valve is made primarily on the basis of patient 
age, valve position, patient comorbidity and the risks and benefits of anticoagulation 
(50). In our environment, the perception is that the relatively young age of our 
patients as well as fear of reoperation informs the choice of mechanical prostheses in 
spite of the fact that many patients may not have access to proper anticoagulation 
monitoring. This has prompted some workers in our centre to recommend fixed-dose 
rather than adjusted-dose anticoagulation regimens (37). 
 
2.4 Valve replacement 
 
As has been indicated above, heart valves can be replaced with either mechanical or 
tissue prostheses. The current standard mechanical valve commonly implanted is the 
bileaflet valve. Tissue valves involve either xenografts or allografts (homografts). 
Valve replacement was first carried out in 1960 and, with respect to rheumatically 
damaged valves, is still commonly performed in developing countries where these 
valves are often irreparable. Valve replacement is performed under cardiopulmonary 
bypass support on the non-beating heart to provide a bloodless operative field. 
 
2.5  Valve Repair/ Reconstruction 
 
2.5.1  Closed Mitral Commissurotomy 
 
This was one of the earliest forms of repair for the mitral valve with the advantage 
of avoiding cardiopulmonary bypass which was not widely available in the early 19th 
century when digital (using a finger) commissurotomy was introduced. It entailed 
either digitally prising the mitral leaflets apart at the anterolateral and the 
posteromedial commissures, or with the aid of a Tubbs dilator, without direct 
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visualization. Early reports showed that valuable relief was especially provided to 
young patients with progressive symptoms of rheumatic mitral stenosis. Figures 
such as 86%, 75% and 62% symptomatic improvement for the first, third and fifth 
year were quoted by some workers from China, however prolonged follow up 
revealed the incidence of re-stenoses as high as 30% - 40% after 10 years (13). 
Another drawback was the inability to visually assess the mitral valve and make 
correct diagnoses of the pathology, therefore giving inconsistent results. Another 
objection to the procedure was the difficulty in obtaining complete relief of the 
stenosis without producing mitral insufficiency. 
With the progress in cardiopulmonary bypass and myocardial protection, closed 
commissurotomy gave way to open commissurotomy. However, this procedure may 
still be relevant in developing countries where access to open heart surgery is 
difficult (51), (52). 
 
2.5.2  Open Mitral Commissurotomy 
 
The era of open commissurotomy commenced in 1956. It has, however, become 
less popular as mitral valve replacement with durable prosthesis is now preferred. 
Another procedure which has further reduced the number of patients available for 
commissurotomy is percutaneous transseptal mitral commissurotomy which was 
introduced in 1984. Some studies have shown that mitral commissurotomy results 
in better long-term survival rates and fewer valve-related complications when 
compared to valve replacement (53). 
 
2.5.3  Mitral Valve Repair 
 
Surgical valve repair for mitral regurgitation has significant advantages over valve 
replacement. This is especially crucial in patients from developing countries since it 
obviates the problems of anticoagulant monitoring and bleeding complications. 
Furthermore, coumarin is largely contraindicated in women of child-bearing age. 
This advantage is evidenced in degenerative mitral valve disease common in 
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developed populations, but the benefits of repair are questioned in rheumatically 
damaged valves in which the leaflets may look relatively normal on macroscopic 
examination but harbor microscopic inflammatory cell infiltration leading to 
progressive fibrosis and leaflet deformity. The overall freedom from valve failure 
after repair in one report was only 66% and thought to be the result of rheumatic 
pathology after a mean follow up of 5 years (24). 
In the setting of endocarditis, controversy still exists as to the success of mitral valve 
repair, but more and more studies are beginning to show better early and late 
mortality as well as event-free survival when compared with replacement (54). This 
has been possible with the advancement of complex repair techniques including 
leaflet and commissural reconstructions. The key to success remains adequate 
debridement of all infected or devitalized tissue.   
 
2.5.4  Balloon valvuloplasty 
 
Percutaneous mitral balloon valvotomy was introduced in 1985 for the treatment of 
selected patients with isolated mitral stenosis. This procedure is ideal for patients 
who are candidates for surgical commissurotomy, especially those with non- 
calcified pliable mitral valves and no left atrial thrombus. It avoids thoracotomy for 
closed commissurotomy which is still performed in some developing nations where 
cost and lack of balloon catheters are continuing problems. 
Some studies report 10 year continued good functional results in patients who had 
immediate procedural success (55). 
 
2.6. Outcome of primary valve surgery 
  
Outcome of valve replacement depends on many factors including patient profile, 
pathology and, probably, geography. It must, however, be stated that much 
morbidity and mortality is a direct consequence of the interaction between the 
patient and operated valve(s), although patient variables may be more responsible 
for outcomes than an operated valve.  
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It has been difficult to understand the role that various patient variables exert on 
operative mortality for a multitude of reasons. Many studies have reported on small 
numbers in specific subgroups of patients thereby having incomprehensive analyses, 
while some have been reluctant to publish high-mortality data from complex 
procedures. Again, there has been a lot of confusion from patient classification and 
changing results over time as a result of evolution of prognosis. 
Traditional predictors of operative morbidity and mortality may no longer have as 
important an impact on clinical outcomes as they used to have. Therefore, periodic 
assessment of a surgical population is necessary to identify a changing demographic 
profile. 
 
2.6.1 Determinants of Operative Mortality 
 
The Society of Thoracic Surgeons (STS) database which records more than 70% of 
US adult cardiac surgical procedures is typically used to generate a simple but 
comprehensive risk factor analysis of operative mortality (56). 
2.6.1.1 Acute Presentation 
The most striking factor observed was acute presentation, associated with a 2-fold 
increase in operative mortality. One disappointing trend noted was a 42% increase in 
acute presentation over the decade studied. The reason for this is not clear. Cardiac 
clinicians, however, need to intensify efforts to emphasize earlier surgical referral 
for all types of severe valve lesions before urgent or emergency intervention is 
required. 
Although some patients are obligatory acute presenters such as in the case of aortic 
dissections and endocarditis, many more have already been evaluated for surgery for 
a while and then are suddenly hospitalized with pulmonary edema requiring surgery. 
Obviously, these patients should have been operated much earlier.  
In populations with low socioeconomic status, presentations are usually late and 
patients are frequently in grave hemodynamic condition. Surgeons then often have 
no choice but to attempt to salvage these patients as they virtually have no prospect 
for successful medical treatment or survival without operation. Kinsley et al. from 
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South Africa reported a 77% early salvage rate and a 52% 3-year actuarial survival 
in a series of 170 patients over a 4!-year period. Among the five subgroups studied, 
including infective endocarditis, acute rheumatic carditis, previous valve operation, 
acute-on-chronic disease and miscellaneous disease, excellent survival of patients 
was noted in the infective endocarditis group (91% at 3years). The 3-year actuarial 
survival of hospital survivors in patients with acute rheumatic carditis and previous 
valve operation was only 51% and 65% respectively (57). 
Even though there is reluctance to operate on acute rheumatic carditis because of 
concomitant myocarditis, it may become imperative as there is frequently a 
mechanical valvular impediment.  
al Kasab et al. reported on six patients with acute rheumatic carditis and intractable 
left ventricular failure, all in class IV New York Heart Association (NYHA) 
classification, from the Kingdom of Saudi Arabia. They attributed the severe 
hemodynamic deterioration in their patients to be due to valvular structural 
insufficiency as opposed to those patients in which severe congestive heart failure 
was as a result of poor left ventricular function with minimal valvular insufficiency 
in which valvular surgery may be of no value. Their results showed that over a mean 
follow-up period of two years, no mortality was recorded and all six patients had 
improved to NYHA class I-II (58).  
There is a direct relationship between timing of surgery and risk of primary and re-
operative valve replacement, making determination of optimal timing an important 
issue. Patients with no or minimal symptoms in NYHA class I-II prior to surgery, 
show excellent results both short- and long- term, leading to a tendency to perform 
surgery earlier (59). 
  
2.6.1.2 Tricuspid valve procedures 
Many of the patients requiring this procedure are usually very ill with chronic 
systemic venous hypertension leading to hepatic and renal failure. Post-operative 
management is also usually challenging. 
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2.6.1.3  Re-operation 
Reoperation has been identified as another important preoperative variable but is 
thought to become only significant when more complex lesions are to be tackled. 
The factors influencing outcome of re-operations are further highlighted later. 
 
 
Figure 6: Survival following re-operation in a study of 92 patients (60). 
 
 
In a study of 92 patients who underwent re-operation (Figure 6), the survival rate was 
significantly lower compared with that of patients who had not required reoperation 
during the same period (p<0.0001) (60). 
  
2.6.1.4  Age 
In the last decade there have been complex changes in the patient population with 
more patients with advanced valvular disease being submitted for surgery. The 
demand for cardiac surgical procedures in the very elderly is also expected to 
increase with time as life expectancy increases. Elderly patients with significant co-
morbid conditions are increasingly being offered surgery.  
Advancing age subjects the heart to fibrosis and calcification such that senile aortic 
stenosis is one of the most prevalent valvular lesions in the elderly but this may be 
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relatively well tolerated in patients despite their years, unlike mitral valve disease 
which is less well tolerated. The successes recorded are a testimony to the improved 
medical and surgical care of the cardiac patient. Guyton and coworkers 
prospectively examined the profile of 2,972 patients undergoing heart valve 
replacement over a ten year period and showed that, although older and sicker 
patients were managed, outcome remained constant with significantly reduced 
length of hospital stay (61). 
Similarly, improved early results following heart valve surgery have been reported 
by Hellgren et al. in a ten year period involving 2327 patients (62). 
 
In contrast, Grunkemeier (63) found that the older the patient at the time of 
prosthetic heart valve implantation, the lower the 10- to 20-year survival rate (Figure 
7), a phenomenon most likely due to a greater incidence of significant associated 
comorbidities. 
 
 
Figure 7: Survival after PHV replacement by patient’s age at time of implantation (63). 
 
2.6.1.5  Gender 
It is known that gender differences affect the pathophysiology of valvular heart 
disease, with women having a 5% to 10% higher cardiac output at any level of 
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submaximal oxygen uptake than men. This is attributed to lower hemoglobin in 
women. The higher cardiac output implies a higher valve gradient, which is 
important when calculating valve area. This becomes even more important when one 
realizes that normal pregnancy is associated with a 30% to 50% increase in blood 
volume and cardiac output. Also, because women are on average smaller than men, 
it is best to index for body size when performing valve calculations (19). 
• Mitral stenosis has a 3:1 preponderance among females, and calcification of the 
valves tends to occur later in women providing a longer time window in which 
balloon valvuloplasty can be performed (19). 
• Aortic valve disease, such as bicuspid valves and non-rheumatic aortic stenosis 
have nearly a 3:1 male predominance in clinical and autopsy studies (64).  
 
2.6.1.6  Race 
Previous studies had shown the black race to be an independent predictor of 
increased mortality after coronary artery bypass graft (CABG) surgery (65). 
However, based on STS data, Bridges and co-authors found that there was no 
significant difference in risk-adjusted mortality between white and black patients 
studied for either mitral valve replacement (MVR) or aortic valve replacement 
(AVR). Black patients, however, were more likely to suffer certain complications, 
including renal failure and prolonged ventilation. Postoperative stay greater than 14 
days and reoperation for bleeding were also significantly increased among the black 
race (66). In a symposium focused on ‘Understanding Disparities in Cardiovascular 
and Thoracic Surgical Outcomes in African Americans’, Bridges noted that there 
has not been a study specifically investigating the role of race as an independent 
predictor of mortality. He did however note that racial bias on the part of the 
referring physician may be implicated, as evidence suggesting that neither disease 
severity, availability of health insurance nor socioeconomic status could explain the 
observed differences compared to whites (65). 
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2.6.1.7 Demographics of the Western Cape 
The Chris Barnard Division of Cardiothoracic Surgery at GSH, one of five other 
referral centres, is a tertiary hospital unit serving a large indigent population of the 
Western Cape. This province probably has the greatest mix of first and third world 
dynamics. 
According to 2001 census figures (67), of the 4.5 million estimated population, more 
than half of the Western cape population were of the Coloured racial group (Figure 
8) with 17% of population aged 15-65 being unemployed. The largest age group 
falls between 25-44 years (33%). This is traditionally the most active age bracket. 
Very few are older than 65 years (5%). 
 
 
Figure 8:  Racial distribution of the Western Cape (67) 
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Figure 9: Average annual income of Western Cape racial groups (67) 
The majority of the population represented by blacks and coloureds (80%) also fall 
into the lower income bracket (Figure 9). 
 
Educational Level 
 
 
Figure 10: Educational levels in the Western Cape (67) 
 
There is a high level of educational attainment in the Western Cape with < 5% 
remaining unschooled (Figure 10). 
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2.6.1.7  Prosthesis-patient mismatch  
Ever since Rahimtoola in 1978 proposed the term ‘prosthetic-patient mismatch’ 
(PPM) to describe high postoperative transprosthetic gradients despite normally 
functioning prostheses, it has become a more frequent problem than originally 
believed and it may have a significant impact on the long term results of valve 
surgery.  
It has been demonstrated that to avoid any significant gradient at rest or during 
exercise, the indexed Effective Orifice Area (EOA) should ideally be no less than 
0.85 to 0.90cm2/m2. 
PPM has been recognized by the American STS and has been identified as a 
nonstructural hemodynamic abnormality rather than being due to an intrinsic defect 
of the prosthesis. 
The incidence of PPM is estimated to be about 52% of patients with a stented 
bioprosthesis (68). The consequences of PPM include excessive resting residual 
transvalvular gradients which double during exercise, and are associated with 
persistent left ventricular hypertrophy. This leads to left ventricular diastolic 
dysfunction with heart failure and arrhythmias. 
 
2.6.2. The EuroSCORE Scoring System 
 
Many scoring systems have been developed in the past to aid in predicting mortality 
following cardiac surgery. These include Parsonnet, The Cleveland Clinic coronary 
scoring system and the UK Society of Cardiothoracic Surgeons Risk score. These 
older systems were developed from institutional and national databases and have 
given way to the European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) introduced in 1999 which is based on a 20,000 patient database 
drawn across eight European countries and has been developed for the  prediction of 
in-hospital mortality after adult cardiac surgery.  
The standard EuroSCORE system consists of three risk groups: low risk (0-2) with 
an expected mortality under 2%; medium risk (3-5) with an expected mortality 
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under 5%; and high risk (>6) with an expected mortality greater than 10%. 
EuroSCORE is effective for both early and long-term mortality prediction after 
cardiac surgery (69). Two different scoring systems exist for the EuroSCORE 
namely the additive model - a score that can be calculated by simple arithmetic - and 
the logistic model - which is more extensive and requires computer based 
calculations. It has been observed that the additive model tends to underestimate risk 
in very high risk patients while conversely overestimating risk in low and moderate 
risk patients.  
The EuroSCORE system has been tested with good correlation in several local 
populations around the world including Europe, Japan, Scandinavia and the USA. In 
a validation study in Australia, using the database from the Australian Society of 
Cardiac and Thoracic Surgeons (ASCTS), the additive and logistic EuroSCORE 
were unable to accurately predict outcomes (70). It is therefore used with caution for 
risk-adjustment or risk-prediction in Australia. 
Unfortunately, this system is yet to be validated in Africa with its unique spectrum 
of cardiovascular disease. It may be necessary to modify the EuroSCORE to suit the 
African population which is clearly distinct from European or American 
populations. It is interesting to note that the EuroSCORE was developed because of 
the inappropriateness of extrapolating North American patient population figures 
which ‘may’ not apply to European practice (71).  
While validating the EuroSCORE in North America, it was observed that there were 
important differences between the European and American populations. American 
patients were older, with proportionately more females. American patients were also 
associated with a higher incidence of comorbidity (respiratory, vascular, 
neurological and renal). Endocarditis had a higher incidence in Europe. All these 
differences were highly significant (72). 
To facilitate an African modification of the EuroSCORE, the establishment of a 
South African, that is a national, Cardiac and Thoracic Surgery database is certainly 
long overdue. The creation of a national database is crucial to the proper assessment 
of outcome. This ought to be the cornerstone of developments in cardiac surgery as 
it allows quality assessment and meaningful comparison and improvement of 
outcome. 
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2.6.3  Outcome 
 
The consequences of these morbid events include reoperation, valve-related 
mortality, sudden unexplained death and permanent valve-related impairment which 
includes neurologic or other functional deficits. 
In assessing outcome of valve replacements, the term ‘major adverse prosthesis-
related event’ (MAPE) has been developed, defined as the composite outcome of 
any reoperation, major bleeding, thromboembolic event, or endocarditis during the 
late follow-up. In the last decade there have been complex changes in patient make-
up with more patients with advanced valvular disease being submitted for surgery. 
Elderly patients with significant co-morbid conditions are increasingly being offered 
surgery. The successes recorded are a testimony to the improved medical and 
surgical care of the cardiac patient. Guyton and coworkers prospectively examined 
the profile of 2,972 patients undergoing heart valve replacement over a ten year 
period and showed that although older and sicker patients were managed, outcome 
remained constant with significantly reduced length of hospital stay (61). Similarly, 
improved early results following heart valve surgery have been reported by Hellgren 
et al. in a ten-year period analyzing 2,327 patients (62). This group also 
recommended surgery in the early stages of valvular disease to improve long-term 
outcome. 
There is a direct relationship between timing of surgery and risk of primary and re-
operative valve replacement, making determination of optimal timing an important 
issue. Patients with no or minimal symptoms, NYHA class I-II, prior to surgery 
show excellent results both short and long term, leading to a tendency to perform 
surgery earlier (10). 
 
2.7 Reoperative valve surgery  
  
In the early years of cardiac surgery, most reoperations were carried out for 
structural valve dysfunctions, including fabric fatigue in fabric reinforced 
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prostheses, and lipid absorption and poppet swelling in the early Starr-Edwards 
valve models. This often happened acutely with resultant emergency conditions and 
high mortality. In the mid-70s, prophylactic replacement of the Braunwald-Cutter 
valve and other cloth covered valves for hemolysis or cloth wear were accompanied 
by extremely low mortality. Most reoperations today are due to paravalvular leaks, 
prosthetic valve thrombosis, prosthetic valve endocarditis and lately, structural 
degeneration of bioprosthetic valves implanted from the late 70s and 80s (73). These 
prosthetic valve complications are further discussed below. 
 
2.7.1 Prosthetic Valve Complications 
 
2.7.1.1 Prosthetic valve thrombosis 
Mechanical prosthetic valves are particularly prone to acute prosthetic thrombosis, 
usually as a result of failure of anticoagulation (74). The incidence of prosthetic 
valve thrombosis can be as high as 13% in the first year in any position and as high 
as 20% in the tricuspid position. There is still a risk of thrombosis even with 
adequate anticoagulation of between 1% to 4% per year (75).  
In developing economies like South Africa, where there is a lack in certain areas of 
proper follow-up and anticoagulation monitoring, this is not uncommon as many 
patients are unable to access INR facilities near where they live. This has prompted 
some workers to recommend fixed-dose rather than adjusted-dose anticoagulation 
regimens (37). 
Emergency or urgent surgery has been the mainstay of management, with 
replacement of the prosthesis, but thrombolysis has gained ground, although there 
are no randomised trials evaluating surgery with thrombolysis (75). Bioprosthetic or 
homograft valves on the other hand do not require long-term anticoagulation unless 
the patient has a significant risk of thromboembolism or has had a thromboembolic 
event with their prosthesis. In the first three months however, the current American 
College of Cardiology / American Heart Association guidelines recommend 
anticoagulation with warfarin because of the increased risk of thromboembolism 
before the exposed surfaces of stented  bioprosthesis endothelialize (76). 
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Figure 11: Prosthetic valve thrombosis (77) 
 
2.7.1.2  Pannus 
Pannus is a membrane of granulation tissue as a response to healing that often 
causes prosthetic valve obstruction. It is very difficult to differentiate it from 
thrombus but duration of symptoms and adequacy of anticoagulation are helpful in 
differentiating thrombus from pannus formation. The use of transesophageal echo 
(TEE) can assess the mechanism and etiology of obstruction. Thrombus is overall 
larger than pannus and often extends into the left atrium in prosthetic mitral valves. 
The best TEE parameter that differentiates the two entities is the ultrasound intensity 
of the mass. A videointensity ratio of <0.7 had the best negative predictive value for 
thrombi. A high negative predictive value for thrombus would allow detection of 
most thrombi and therefore identify patients with pannus formation and in whom 
one can forgo attempts at thrombolytic therapy and instead initiate immediate valve 
surgery, particularly when presenting with hemodynamic instability. 
The combination of clinical parameters and ultrasound density of the mass by TEE 
further strengthens the differentiation of thrombi from pannus formation and may 
therefore be of value in refining the selection of patients for thrombolysis (78). 
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2.7.1.3.  Prosthetic valve endocarditis 
This is a catastrophic complication following valve replacement with an incidence 
of about 0.3% to 1.2% per patient year and cumulative risk of 5% at 10 years (79). 
Despite improvements in antibiotic prophylaxis, the incidence does not seem to be 
declining with a mortality of between 2% and 60% in different reports (80). 
 
2.7.1.4.  Structural Failure ( Structural valve dysfunction – SVD) 
Mechanical Valves: It is very uncommon for mechanical prostheses to undergo 
structural failure. For example, there have been no failures reported with the original 
Medtronic-Hall valve in approximately 130,000 implants while the D16 variation 
reported 4 disc fractures in approximately 80,000 implants and has since been 
removed from the market (81). In the event of structural failure of a valve, this is 
reported to the manufacturers for appropriate actions. 
The latest occurence of structural failure was with the TRI Technologies (TT) valve, 
a low-profile bileaflet prosthesis commercialised in Brazil. After three valve-related 
deaths occured between 2002 and 2004, the valve was promptly removed from the 
market. Patients who had received the valve underwent a prophylactic replacement 
program with St Jude valves (82).  
Freedom from reoperation for currently available mechanical valves is greater than 
95% at 10 years and greater than 90% at 15 years (43). 
 
Tissue Valves: Bioprosthetic valves on the other hand will inevitably undergo 
structural degeneration which is the leading cause and most frequent indication for 
reoperation in patients with bioprosthetic valves (83), (84). 
The mechanism of degeneration is mainly due to increased calcification in the 
cuspal commissures and basal attachments extending later into the center of the 
leaflet, largely because these parts receive the greatest hemodynamic stress and 
become stenosed and incompetent. Currently, glutaraldehyde is the standard fixative 
in the processing of tissue valves with no alternative yet in sight. There is some 
contention on the role of glutaraldehyde in the calcification process, with some 
workers suggesting that glutaraldehyde itself is partly responsible for calcification of 
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xenograft tissue (85). However, recently, Zilla et al. showed increased 
glutaraldehyde concentrations conversely significantly mitigated bioprosthetic tissue 
calcium levels in the sheep and the rat. Contemporary valves may therefore be using 
suboptimal glutaraldehyde concentrations rendering them more immunogenic and 
thus proinflammatory (86). Prolonging the lifespan of these valves will require 
inhibition of this mineralization process through the use of different chemical 
anticalcification agents (31). Such anticalcification agents such as surfactants, 
biphosphonates and  alpha-amino oleic acid have been extensively studied. 
Recently, Zilla et al. showed even further augmentation of anticalcification 
properties of alpha-amino oleic acid combined with carbodiimide (87), suggesting 
that much research is still required in this field. 
Both mechanical and tissue valves are, however, not immune from endocarditis, 
dehiscence, perivalvular leak and pannus formation, amongst other complications. It 
is therefore difficult to adequately compare the two different valves because of 
differences in the mechanism of failure.  
With the availability of new stentless valves and homografts, more aortic 
bioprosthesis are being implanted in progressively younger age groups (88) with the 
knowledge that these valves would only last between 12 to 15 years (89). The 
decision to use a bioprosthesis for primary isolated AVR requires the lowest 
possible reoperative mortality to improve the long-term outcome in these patients.   
The cryopreserved allograft (homograft) is believed to be superior to the xenograft 
and 4˚C-stored allograft valves in patients younger than 60 years while there is no 
difference for all three in patients older than 60 years. Allograft valve failure appears 
to be a complex interplay between mechanisms such as leaflet degeneration, 
geometric distortion, changing mechanical properties of the leaflet tissue, and aortic 
root dilatation (90). Furthermore, the allograft valve has an additional advantage 
over both xenograft and mechanical valves for aortic valve replacement in the 
setting of endocarditis with a lower probability of recurrent endocarditis (91). 
 
2.7.1.5.  Periprosthetic leak (PPL) 
Periprosthetic leak (PPL) occurs in 1% to 3.5% of patients after aortic valve 
replacement while in the mitral valve, the incidence is as high as 13%. Factors 
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known to predispose to this problem include prosthetic valve endocarditis, dilated 
cardiomyopathy, ischemic mitral regurgitation and of course suture or surgeon 
related technique. 
The role of anatomical factors in the occurence of periprosthetic leak in both the 
aortic and mitral positions has not been properly studied. The current thinking is that 
the role of anatomical predisposition is much more than previously thought. 
G. DeCicco et al. have suggested in two different reports (92), (93)  that the majority 
of PPL in the mitral area occur at the anterolateral and posteromedial segments of 
the mitral valve annulus, whereas the area of the aortic annulus between the middle 
of the right coronary sinus and the middle of the non-coronary sinus were more at 
risk of developing PPL.   
 
2.7.2.  Factors influencing mortality 
 
It was to this end that the National Cardiac Surgery Database of the STS which 
contains records of 86,580 patients was created. In the analysis of the ten year data 
with 51 preoperative variables, Jamieson and colleagues report that re-operative 
mortality rates are only significant when first operations were elective or urgent but 
not with emergent and emergent-salvage operations (94). Ideally, the hospital 
mortality after valve re-replacement should be identical to that of the equivalent 
primary valve procedure to improve the long term outcome especially with 
bioprostheses (88). 
The beauty of the STS Database is that institutions can enter their patient population 
data and obtain direct risk-adjusted comparisons with the national standard (94). 
Many workers will agree that the overall mortality for first reoperations is about 
10% (42). However, the risk reduces to about 3% in patients who had initial 
reparative procedures, for example mitral valve repairs, or who underwent surgery 
for new native valve disease. This encourages the use of valve repair where possible 
because the risk at reoperation is not increased (42). In the past, reoperative surgery 
has been associated with a considerably higher operative mortality than primary 
valve surgery. Poor preoperative left ventricular function and duration on 
cardiopulmonary bypass, but not the number of reoperations has been correlated 
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with operative mortality (4). Another important predictor of hospital mortality is the 
NYHA classification. This has led some workers to suggest that patients with 
structural dysfunction of bioprostheses may be operated on, even when 
oligosymptomatic (73). 
Vogt et al. agrees that emergency surgery is the most important factor responsible 
for high early mortality and that early reoperation of failing bioprosthesis is advised 
to reduce the incidence of emergency surgery (86). They therefore emphasize proper 
timing of the reoperation with early reoperation improving the long-term outcome of 
patients with tissue valves. 
SVD can be identified two to three years before the patient becomes symptomatic 
and needs reoperation. Regular Doppler echocardiographic follow-up examinations 
should be carried out starting no later than six to seven years after implantation (31).  
A special category of ‘high risk’ patients undergoing reoperation are the 
octogenarians. The population >80 years is expected to rise to 25 million in 
America, that is one in twelve Americans, by 2050. In a study by Kirsch et al. the 
indication for reoperation in this group as a result of degeneration of previously 
implanted bioprostheses accounted for 50% of the study population. Twenty seven 
percent had  new valvular diseases while 18% had progression of rheumatic valvular 
heart disease. Five percent (1 patient) had prosthetic valve endocarditis. The 
mortality  in octogenarians from their study was as high as 38% (95). Ghosh and co-
workers (96) advocat  very careful screening in this high risk group to achieve a 
beneficial outcome. It will be necessary to identify contraindications to surgery, a 
practise amounting to rationing of medical care in this vulnerable aged subset, but 
which promises to ensure definitive benefits in reoperative candidates. 
 
2.7.3  Surgical Technique 
 
2.7.3.1  Resternotomy 
Resternotomy is technically demanding, and careful attention to not go beyond the 
posterior table of the bone with the oscillating saw is essential to avoid 
complications. Most authors recommend dividing the posterior table using a 
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combination of scissors and lateral retraction. Preoperative computerised tomogram 
(CT) scans to detect aortic and right ventricular adhesions to the sternum have 
significantly dropped the incidence of sternotomy-related injuries (97). The exact 
incidence of this dreaded complication is unknown due to lack of consistent 
definition and partly due to underreporting as it may imply a technical error (98). 
Analysing 552 patients who underwent reoperative valvular surgery, Husebye et al. 
had a 4% complication rate directly related to sternal opening with two operative 
deaths from coronary artery graft laceration and laceration of the aorta with 
subsequent exanguination (73). Attempts at resternotomy should be abandoned once 
major hemorrhage occurs and  peripheral cannulation using the femoral vessels 
should be immediately carried out. 
Alternative perfusion sites using the groin and the axillary routes have been 
developed and preparations for emergency cardiopulmonary bypass should be 
completed prior to beginning the resternotomy. Proper use of deep hypothermic 
cardiac arrest and improved myocardial protection. have also contributed 
significantly (99).  
Minimally invasive valve procedures have gradually become more acceptable in the 
setting of reoperations. Partial upper resternotomy using an inverted-T incision has 
been refined since it was first used in 1996 (100). There has been an evolution of 
techniques in reoperative valve surgery. This has contributed significantly to the 
reduction of mortality. Major advances include the development of alternative 
incisional approaches to minimize injury to adherent cardiac structures. Right 
anterolateral thoracotomy is a safe alternative to resternotomy for mitral valve 
replacement. It provides excellent exposure of the mitral and tricuspid valves and 
avoids the dissection of the pericardium. 
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CHAPTER 3:  PATIENTS AND METHODS 
 
3.1. Introduction 
 
This study is a retrospective analysis of valve and valve redo-procedures performed 
at Groote Schuur Hospital (GSH) within the University of Cape Town’s Chris 
Barnard Division of Cardiothoracic Surgery during a 16 year period in order to 
examine short term outcomes of valve surgery as well as factors that may influence 
the time to failure of these valves. 
The main thrust of this study was to determine the demographics and presentation of 
patients and to assess whether the currently preferred choice of prostheses could be 
validated by retrospective examination of longer term outcomes. 
From 1993 to 2008, consecutive patients who underwent heart valve procedures 
were captured by our ‘Summit’ database which commenced in 1993 and 
subsequently by a database developed in-house which replaced it in 2003. We did 
not include patients prior to 1993 because there was no database in existence during 
that period and complete records were infrequent. Even in the original Summit 
database, demographic and comorbidity data or type of valve implanted, for 
example, was incomplete although core data, that is relating to the etiology, the 
surgical procedure performed and short-term outcome, were nevertheless available. 
In some cases though, patients operated from 1993 but prior to 2003 (the capture 
period for the Summit database) were excluded from the study when even these core 
parameters were unavailable. 
In order to better identify the differences between patients with rheumatic heart 
disease and those without, patients who had only single valve procedures were 
selected for analysis to remove the complex interactions of double or triple valve 
procedures with various combinations of incidence of operation and disease 
etiology. 
During the 16 year period (1993-2008), 1,449 patients were thus defined for the 
purposes of this study who underwent first incidence single valve procedures out of 
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a total of 2,939 patients who had 4,145 valve procedures at GSH which included 
single, double and triple valve surgeries. 
Of the 1,449 (study population), 770 (53.1%) patients were identified with 
rheumatic etiology while 679 (46.9%) were non-rheumatic. 
 
3.2. Variables 
 
The following demographics were analyzed in this study: age, sex, race, educational 
status, employment status, housing type and preoperative NYHA class. Other intra 
operative variables include implant type and position, repair or replacement 
procedure and short term outcomes such as ICU stay, hospital stay and 30-day 
mortality. The time to reoperation was assessed as a long term outcome, but was 
severely limited by loss to follow-up of patients not presenting for redo procedures. 
 
3.3. Guidelines for definitions 
 
The following definitions, as established by the Society of Thoracic Surgery 
(http://www.sts.org), were applied in part in this analysis: 
 
3.3.1 Mortality 
Thirty-day mortality (sometimes termed operative mortality) referred to death 
within 30 days of operation regardless of the patient’s geographical location. 
Hospital mortality referred to death within any time interval after operation if the 
patient was not discharged from the hospital. Note that hospital to hospital transfer 
was not considered discharge. In-hospital mortality is one of the most widely used 
measures of outcome for determining the risks/benefits of cardiac surgery (5), (101). 
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3.3.2 Morbidity 
SVD is any change in function (a decrease of one New York Heart Association 
functional class or more) of an operated valve resulting from an intrinsic 
abnormality of the valve that causes stenosis or regurgitation. These are changes 
intrinsic to the valve such as wear, fracture, poppet escape, calcification, leaflet tear, 
stent creep, and suture line disruption of components (e.g., leaflets, chordae) of an 
operated valve. 
Nonstructural dysfunction refers to any abnormality which resulted in stenosis or 
regurgitation, exclusive of thrombosis and infection, not intrinsic to the valve itself. 
Examples include entrapment by pannus, tissue, or suture, paravalvular leak, 
inappropriate sizing or positioning, residual leak or obstruction from valve 
implantation or repair, and clinically important hemolytic anaemia. 
Valve thrombosis refers to any thrombus, in the absence of infection, attached to or 
near an operated valve that occluded or interfered with valve function. 
Embolism - any embolic event that occurred after the immediate perioperative 
period i.e. when anesthesia-induced unconsciousness was completely reversed. A 
neurologic event included any new, temporary or permanent, focal or global 
neurologic deficit. These included transient ischemic attacks (TIA), reversible 
ischemic neurologic deficit (RIND), stroke or permanent neurologic event.      
Bleeding event - any episode of internal or external bleeding that caused death, 
hospitalization or necessitated transfusion. 
Operated valvular endocarditis - any infection which involved an operated valve. 
  
3.4 Statistical Analysis 
 
Values of continuous data were presented as means ± sample standard deviation 
(SD) or as medians plus range, when appropriate. Categorical variables were 
displayed as frequency distributions (n) and simple percentages (%). Univariate 
comparison between the groups for categorical variables was made using the chi-
square and the Fisher’s exact tests when appropriate. Logistic regression was used to 
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examine the relationship between the short and long term outcome variables and 
potential risk factors. Statistical significance was accepted when p < 0.05. 
All statistical analyses were performed using the JMP6.0.2 (SAS,Inc, Cary, NC) 
application on an Apple PowerPC-based Macintosh computer (Apple, 
Cupertino,CA).  
 
3.5 Challenges (Limitations) 
 
This study is particularly challenging because it is difficult to provide medical 
services and conduct research in a disadvantaged population where patient follow-up 
is hampered by an indigent and especially migrant population. Many of our primary 
valve operated patients are lost to follow-up and may undergo re-operation in other 
centers and vice versa, either for prosthesis-related complications or for progression 
of native valve disease, thereby complicating the process of data collation. 
 
A further challenge is the sifting of retrospective data generated from a 4-valved 
organ with various combinations of etiologies, procedures differing from valve to 
valve and even within the same valve, for example repair followed by replacement, 
one or more reoperations on the same valve and a host of other confounding factors. 
Technically speaking for example, a replacement of a previously repaired valve is a 
reoperation but also a first time replacement. So whilst there was no ‘explant’, it 
could easily be coded in a database as a reoperation … without an explant. There are 
countless examples of this kind of ‘impure’ data. To minimize this effect, patients 
who had single valve procedure only were selected for analysis. 
Retrospective analyses too are however flawed because although capable of showing 
association, they cannot reliably determine causation and hence its value is not as 
strong as adequately controlled studies. It is also less likely to suffer the problem of 
‘missing data’ which will also affect the power of the analysis.  
 
Many patients in South Africa still do not have funds to promptly access medical 
attention resulting in poor patient clinical presentation with advanced disease states 
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when and if they finally arrive. This unfortunately translates to very little surgical 
activity, and where it exists, fluctuating numbers of patients benefiting per year. 
This makes it impossible to plan any meaningful service or research. 
This is similar in other sub-saharan countries which are often plagued by inadequate 
human and material resources. In Nigeria, for example, it has been very difficult to 
sustain cardiothoracic services in the few hospitals that have been able to offer them 
since 1974, largely because of the current severe devaluation of the Nigerian Naira 
(currency), making it difficult to procure consumables and other necessary 
equipment. Very few patients in Nigeria are able to afford cardiac surgery whilst 
insurance scheme cover for cardiac surgery is lacking (102). The story is no 
different in Uganda, where the health care budget is less than USD $ 15 per person 
per year (103). 
It is hoped that future prospective studies will be undertaken at GSH which caters 
for a significant percentage of patients from poor backgrounds to distinguish 
between virtual and real risks in the context of the indigent patient. 
We also hope that this study may eventually stimulate the development of a multi-
centre study with the aim of establishing a regional database with large numbers, 
allowing inferences that will be useful in the practice of heart valve surgery across 
the African continent.  
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CHAPTER 4.  RESULTS 
 
Examination of the two cohorts of patients demonstrated a higher female prevalence 
in the rheumatic group (female:male ratio = 1.7) but a more equal distribution, albeit 
with a slight male prevalence, between the sexes in the non-rheumatic group 
(female:male = 0.86; p<0.0001) (Figure 14). The non-rheumatic patients were also 
significantly older by 17 years (Table 4). 
 
Apart from female gender, rheumatic heart disease was significantly associated with 
black and coloured racial groups (p<0.0001), informal housing (p<0.0001) and 
unemployment (p<0.0001) (Table 4). Patient demographic data is displayed in Table 
4 and in Figure 12 through Figure 16. 
Whilst the coloured racial group accounted for the majority of patients in both 
rheumatic and non-rheumatic groups, there was a distinct black majority compared 
to whites (32.7% - black vs. 5.8% - white) in the rheumatic group and a distinct 
white majority compared to blacks (27.1% - white vs. 17.7% - black) in the non-
rheumatic group (p<0.0001) (Figure 13). 
 
The median age irrespective of race in the rheumatic group at the time of valve 
surgery is 42.2 years, compared to 59.6 years in the non-rheumatic group (Table 4) 
with a significant difference existing between racial classes in the rheumatic group 
(36.5yrs amongst Blacks compared to 51.6yrs amongst Whites; p<0.0001) (Figure 
13). Both groups presented largely in poor NYHA class (III & IV) (p<0.0001) 
(Figure 17 and Figure 18). 
 
Non-rheumatic patients were associated with significantly more co-morbidity factors 
such as smoking (p=0.038), renal failure (p=0.005), hypertension (p<0.0001) and 
diabetes (p<0.0001) as highlighted in Table 5. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 52 
Table 4: Patient Demographics 
 
 
 
 RHD (n=770) Non-RHD (n=679) P value 
SEX(M/F) 287/483 366/313 <0.0001 
AGE 
Median (range) yrs 
42.2 (16-81.3) 59.6 (16-85.2) <0.0001 
RACE 
Black (%) 
Coloured (%) 
White (%) 
Asian (%) 
 
252 (32.7%) 
463 (60.2%) 
45 (5.8%) 
10 (1.3%) 
 
120 (17.7%) 
366 (53.9%) 
184 (27.1%) 
9 (1.3%) 
<0.0001 
NYHA 
I 
II 
III 
IV 
 
35 (4.6%) 
279 (36.2%) 
401 (52.1%) 
55 (7.1%) 
 
42 (6.2%) 
203 (29.9%) 
324 (47.7%) 
110 (16.2%) 
<0.0001 
HOUSING 
Formal 
Informal 
n = 539 
439 (81.5%) 
100 (18.6%) 
n = 540 
491 (90.9%) 
49 (9.1%) 
<0.0001 
EDUCATION 
Matric 
No matric 
n = 518 
102 (19.7%) 
416 (80.3%) 
n = 529 
126 (23.8%) 
403 (76.2%) 
N.S. 
EMPLOYMENT 
Employed 
Unemployed 
n = 531 
275 (51.8%) 
256 (48.2%) 
n = 536 
380 (70.9%) 
156 (29.1%) 
<0.0001 
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Figure 12: Demographics of gender and racial class between non-rheumatic and rheumatic 
patients 
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Figure 13: Age distribution of black and white racial groups. 
 
 
 
 
 
Figure 14: Relationship between RHD and gender 
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Figure 15: Housing and RHD 
 
 
 
Figure 16: Employment and RHD 
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Figure 17: NYHA classification of rheumatic patients 
 
 
 
 
 
Figure 18:  NYHA classification of non-rheumatic patients 
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Table 5: Associated co-morbidity factors 
Factor RHD Non-RHD    P-value 
Diabetes n= 42/528 (8.0%) n= 80/496 (16.1%)   < 0.0001 
Smoking n= 258/515 (50.1%) n= 283/500 (56.6%)   0.038 
Renal failure n= 10/533 (1.9%) n= 25/497 (5.0%)   0.005 
Obesity n= 59/295 (20.0%) n= 88/372 (23.7%)   0.260 
Hypertension n= 101/518 (20.0%) n= 203/515 (39.4%) < 0.0001 
Ischaemic Heart Disease n= 60/765 (7.8%) n= 240/659 (36.4%) < 0.0001 
 
The etiology of non-rheumatic disease included calcific degeneration (38.4%), 
ischemic heart disease (14.4%) and myxoma (9.8%). Native valve endocarditis 
accounted for 8% of cases. 
Table 7 highlights the procedural characteristics with 801 mitral (55.3%) and 648 
aortic procedures. There were 190 (23.7%) repairs to the mitral valve. In only 67 
(8.7%) of the rheumatic patients was repair attempted, while 123 (18.1%) of the 
non-rheumatic group had mitral valve repair (p<0.0001). 
Valve replacement was the more common surgical procedure (83.5%) with 864 
(60%) being mechanical. The majority of rheumatic patients (72%) had a 
mechanical prosthesis implanted. There were significantly larger numbers of 
concomitant CABG procedures in the non-rheumatic group (36%) than rheumatic 
(8%); (p<0.0001) (Figure 19). 
 
From the study cohort of 1,449 patients (valves), there were 216 re-operations 
giving a presentation rate for reoperation of 15%. During the 16 year period, 163 
(21.2%) of the rheumatic patients presented for reoperation while only 53 (7.8%) of 
the non-rheumatic group returned for re-intervention (Table 6). Most (70%) of 
implanted valves in both primary and redo surgeries were mechanical. Of the 
patients who received mechanical valves, 15.6% returned compared to 11.5% in the 
case of tissue valve patients (p=0.055). 
The major reasons accounting for patients presenting for reoperation in the 
rheumatic group were progression of the rheumatic process in 36%, prosthetic valve 
thrombus in 26% and endocarditis in 8%. In the non-rheumatic group, degeneration 
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of tissue valve accounted for 23% of reoperations, thrombus in 15%, pannus in 11% 
and endocarditis in 8%. 
 
 
 
Figure 19: CABG performed in RHD 
 
Table 6: Original procedure in those patients undergoing reoperation 
Ratios RHD Non-RHD    P-value 
Aortic:Mitral 42:121 38:15 <0.0001 
Mechanical:Tissue* 79:38 25:11 N.S. 
Repair:Replace 19:144 11:42 N.S. 
* (data was not available for all replacement patients) 
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Table 7: Operative Procedures 
 
RHD 
(n=770) 
Non-RHD 
(n=679) 
P value 
 
Repair 
Mitral 
Aortic 
 
67 
1 
 
123 
48 
 
<0.0001 
<0.0001 
Replace 
Mitral 
Aortic 
 
465 
237 
 
146 
362 
 
Valve type*  
Mechanical 
Tissue 
 
458 (72.2%) 
176 (27.8%) 
 
209 (45.4%) 
251 (54.6%) 
 
<0.0001 
Reoperations 163 (21.1%) 53  (7.8%)  
Simultaneous CABG 60 (8%) 240 (36%) <0.0001 
* (data was not available for all replacement patients) 
 
Analysis of short and long-term outcome is shown in Table 8 and Table 9 
respectively. 
The mean ICU stay in the rheumatic patients was shorter (76.5±113 hours) than in 
non-rheumatic patients (99.3±155.1hours) (p=0.048). However, this was 
independent of the valve type or position. Patients with rheumatic disease had 
hospital stays of 11.5±10.4 days in hospital compared to 13.8±27.3 days for non-
rheumatic patients (p=0.05). Thirty-day mortality occurred in 15 (2%) rheumatic 
patients and 72 non-rheumatic patients (11%) (p<0.0001) (Figure 20). 
Mortality in rheumatic patients was dependent on valve type (tissue > mechanical) 
(p=0.0015), and presence of renal failure (p=0.019). 
Patients presenting with failed mechanical valves did so significantly earlier [4.23 
(0.003-34.3) years] in rheumatic patients compared to non-rheumatic patients [6.91 
(0.01-24.4) years] (p=0.0039) as well as earlier than tissue valves in rheumatic 
patients, which presented with failure after 9.54 (0.11-23.89) years (Figure 21). 
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Figure 20: 30-day mortality in RHD 
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Figure 21: Time to reoperation of valve prostheses used for rheumatic patients
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Table 8: Early Outcome Analysis 
ICU stay (hrs) RHD Non RHD P value 
 
     Overall  
 
     Repair 
     Replace 
 
     Aortic                                                             
     Mitral 
 
     Renal Failure 
     No renal failure 
 
     First incidence 
     Reop 
 
     Hypertensive 
     Normotensive 
 
     Diabetes 
     No Diabetes 
 
     Smoker 
     Non-Smoker 
 
     Obese 
     Non-obese 
 
     IHD 
     Non-IHD 
 
 
76.5±113 
 
66.9±59.6 
77.5±119.3 
 
65.9±84.1
80.9±122.8 
 
125.9±170.2 
71.1±97.5 
 
45(5.9-1127) 
64.5(39.5-1410.8) 
 
59.1±18.2 
75.5±7.3 
 
102.1±23.9 
68.8±5.8 
 
69.6±7.8 
74.6±8.8 
 
59.4±5.3 
88.0±9.6 
 
117.8±30.2 
72.6±6.3 
 
99.3±155 
 
113.2±218.7 
94±122.9 
 
81±82.8 
128.2±224 
 
119.8±23.1 
101±166.9 
 
55.7(0.3-1415.3) 
65.9(38.4-309) 
 
126.0±15.9 
82.6±11.6 
 
176.9±47.3 
91.1±10.9 
 
105.4±10.0 
98.1±16.0 
 
113.2±18.3 
97.5±12.2 
 
143.8±29.6 
83.4±9.0 
 
0.048 
 
0.200 
0.170 
 
0.180 
0.018 
 
0.907 
0.013 
 
0.0003 
0.850 
 
0.006 
0.594 
 
0.169 
0.050 
 
0.037 
0.161 
 
0.031 
0.534 
 
0.592 
0.317 
Repair 
     Aortic 
     Mitral 
 
Replace 
     Aortic 
     Mitral 
 
Replace 
      Mechanical 
      Tissue 
 
- 
69.9±9.0 
 
 
65.9±8.7 
83.6±10.0 
 
 
72.7±7.8 
90.8±19.2 
 
71.6±23.0 
127.7±36.5 
 
 
82.2±7.4 
128.8±30.8 
 
 
92.6±12.9 
98.1±13.8 
 
- 
0.136 
 
 
0.153 
0.078 
 
 
0.187 
0.757 
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Table 8 (continued) 
Hospital Stay (days) RHD Non RHD P value 
 
     Overall 
 
     Repair 
     Replace 
 
     Aortic 
     Mitral 
 
     Renal Failure 
     No renal failure 
 
     First incidence 
     Reop 
 
     Hypertensive 
     Normotensive 
 
     Diabetes 
     No Diabetes 
 
     Smoker 
     Non-Smoker 
 
     Obese 
     Non-obese 
 
     IHD 
     Non-IHD 
 
 
11.5±10.4 
 
12.06±9 
11.5±10.6 
 
11.3±7.5 
11.6±11.6 
 
16.8±14.7 
11.7±10.9 
 
11(1-334) 
12(1-66) 
 
12.2±1.0 
11.5±0.4 
 
15.7±2.0 
11.4±0.5 
 
11.3±0.8 
11.5±0.6 
 
12.5±1.4 
12.1±0.6 
 
11.9±0.6 
11.4±0.5 
 
 
13.8±7.3 
 
15.0±41.6 
13.4±19.9 
 
12.5±21.0 
15.7±34.5 
 
12.6±11.1 
14.3±30.8 
 
11(1-91) 
10(1-75) 
 
12.0±0.7 
12.7±0.6 
 
12.5±1.1 
12.5±0.5 
 
11.8±0.6 
12.5±0.6 
 
15.3±2.0 
14.6±0.9 
 
11.3±0.6 
12.9±0.5 
 
 
0.050 
 
0.620 
0.052 
 
0.430 
0.028 
 
0.380 
0.065 
 
0.600 
0.086 
 
0.826 
0.085 
 
0.144 
0.150 
 
0.594 
0.237 
 
0.230 
0.020 
 
0.598 
0.041 
 
Repair 
     Aortic 
     Mitral 
 
Replace 
     Aortic 
     Mitral 
 
Replace 
      Mechanical 
      Tissue 
 
- 
12.2±1.3 
 
 
11.3±0.5 
11.6±0.6 
 
 
11.5±0.6 
11.6±0.9 
 
9.8±1.0 
12.6±0.9 
 
 
11.7±0.5 
14.7±1.1 
 
 
14.3±0.8 
11.8±0.7 
 
- 
0.804 
 
 
0.607 
0.011 
 
 
0.007 
0.836 
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Table 8 (continued) 
30-day mortality RHD Non RHD P value 
      
     Overall 
 
     Repair 
     Replace 
 
     Aortic 
     Mitral 
 
     Renal Failure 
     No renal failure 
 
     First incidence 
     Reop 
 
     Hypertensive 
     Normotensive 
 
     Diabetes 
     No Diabetes 
 
     Smoker 
     Non-Smoker 
 
     Obese 
     Non-obese 
 
     IHD 
     Non-IHD 
 
 
2.0% 
 
0% 
2.14% 
 
3.36% 
1.32% 
 
20% 
2.1% 
 
 
 
 
2.0% 
2.6% 
 
9.5% 
1.9% 
 
1.2% 
2.7% 
 
1.5% 
2.0% 
 
3.3% 
1.8% 
 
10.6% 
 
14% 
9.45% 
 
9.76% 
11.9% 
 
36% 
9.96% 
 
 
 
 
12.8% 
9.9% 
 
18.8% 
9.9% 
 
9.5% 
10.1% 
 
10.3% 
11.1% 
 
17.9% 
6.0% 
 
<0.0001 
 
< 0.0001 
< 0.0001 
 
0.002 
<0.0001 
 
0.340 
< 0.0001 
 
 
 
 
0.001 
<0.0001 
 
0.293 
<0.0001 
 
<0.0001 
0.001 
 
0.049 
0.0003 
 
0.004 
0.001 
Repair 
     Aortic 
     Mitral 
 
Replace 
     Aortic 
     Mitral 
 
Replace 
      Mechanical 
      Tissue 
 
- 
0.0% 
 
 
3.4% 
1.5% 
 
 
1.1% 
5.7% 
 
16.7% 
13.0% 
 
 
8.8% 
11.0% 
 
 
7.2% 
11.6% 
 
- 
0.0008 
 
 
0.011 
<0.0001 
 
 
<0.0001 
0.041 
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Table 9: Late Outcome 
Median time to redo 
(range) yrs 
RHD Non RHD P value 
Mechanical 
Tissue 
4.23 (0.003-34.3) 
9.54 (0.11-23.9) 
6.91 (0.01-24.4) 
7.69 (0.07-17.1) 
0.0039 (Wilcoxon) 
<0.0001 (Wilcoxon) 
 
 
 
 
Figure 22: Repair vs replacement in rheumatic mitral valves 
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Figure 23: Repair vs replacement in non-rheumatic mitral valve 
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CHAPTER  5.  DISCUSSION 
 
The practice of heart valve surgery in a threshold country such as South Africa 
clearly reveals differences in patient characteristics as there is a complex mix 
between the different population groups. There is a similar challenge in areas in 
Australia and New Zealand with similar population dynamics, that is a mix of both 
first and third world patients (18). There are therefore obvious challenges in 
performing such surgery in this environment and care should therefore be taken to 
tailor procedure to patient and not vice versa.  
Interestingly, though, many of the studies available on heart valve surgery in 
rheumatic heart disease come from countries where incidence of rheumatic heart 
disease has drastically declined (104). In developing countries, where the bulk of 
cases arise, it is very difficult to publish definitive conclusions as a result of poor 
data collation and therefore analysis (22). 
More than 80% of the population of the Western Cape, the home of GSH, are 
members of the Coloured and Black racial groups. These same groups form the 
majority that live in poor housing, overcrowded situations and poor socio-economic 
circumstances which are risk factors for the development of rheumatic fever (23). In 
fact, the racial distribution of rheumatic patients seen in our unit during this period is 
an accurate reflection of the 2001 census population figures of the Western Cape 
(105). 
The significantly younger age of the Black patient at the time of surgery underscores 
the grave economic impact of valvular heart disease in this developing country. This 
fact also underlines many issues for urgent attention, including rheumatic fever 
prevention and choice of heart valve prosthesis which have been previously 
highlighted by others (9). It is clear that much more needs to be achieved in the area 
of prevention. 
The onset of rheumatic fever, which is about 10 - 15 years earlier than the 
development of established rheumatic heart disease (6), should stimulate concerted 
attempts at disease prevention. Rheumatic heart disease continues to be the leading 
etiology associated with valvular heart disease requiring valve replacement (4) 
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corroborated by our study which showed that 53.1% of the patients (valves) 
operated had a rheumatic etiology.  
Rheumatic fever is a disease of poverty (23) and rheumatic heart disease is still 
widely prevalent in developing countries all over the world but, due to poor facilities 
for registration of cause of death, reliable statistics are difficult to obtain. In 1995, 
the WHO estimated that 12 million people were affected by rheumatic fever or 
rheumatic heart disease worldwide, resulting in 400,000 deaths annually (106). It is 
also estimated that about 282,000 new cases arise every year (26). Unfortunately, 
most countries where rheumatic fever is prevalent do not have the financial 
resources nor the sophisticated medical services to treat the long term sequelae of 
chronic valvular heart disease. 
Pharyngeal infection with its causative organism, GAS, is more common in the areas 
of overcrowding and poor socioeconomic conditions. Our study surprisingly showed 
a predominance of formal housing in both subsets although a significantly stronger 
association of informal housing was seen in the rheumatic subset (p<0.0001). It must 
be emphasized that exposure to rheumatic fever occurs about 10 to 15 years before 
established valve disease (6) during which time there may be a change of living 
standards, as may have occurred in South Africa since 1994. This change in living 
standards may explain the decline of cases in the developed world in the USA for 
example, where the incidence of rheumatic fever has fallen from 100 per 100,000 
population at the turn of the century, to 45-65 per 100,000 between 1935 and 1960, 
and further to 2 per 100,000 currently (106).  
Irrespective of racial background, 62% of our study population presented in poor 
clinical state of NYHA III and IV. This high figure brings to question the access of 
the population to prompt and effective medical care which becomes even more 
pertinent after insertion of mechanical prostheses which tend to fail acutely resulting 
in significant morbidity and mortality if intervention is delayed.  
Surgery for rheumatic heart disease in the young in developing countries such as 
South Africa has been aptly described as ‘attempting to mop up the water on the 
floor while leaving the faucet open’ (9) as many of these patients return to living 
conditions at high risk for rheumatic fever. 
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The scourge of tuberculosis (TB) and human immunodeficiency virus (HIV) throws 
more complexities at this same group of individuals. 
Rheumatic heart disease was significantly associated with female gender, black and 
coloured racial groups, informal housing and unemployment. Previous studies have 
highlighted gender differences in valvular heart disease (107), (108)  with a 3:1 
female predominance in mitral stenosis and a reversed 3:1 male preponderance in 
bicuspid aortic valve and-non rheumatic aortic stenosis (108). 
We found an almost 2:1 female predominance in rheumatic disease patients and a 
reversal of this trend in non-rheumatic patients which parallels the findings of the 
previous authors. These studies on gender differences have implicated hormonal 
imbalances in pathophysiology and outcome (107), but further studies need to be 
done to understand the exact relationship that exists between gender and 
pathogenesis.  
Pregnancy is also known to accelerate the deterioration in clinical presentation 
because of significant increases in the blood volume and cardiac output in an already 
compromised heart (108) contributing to early presentation in pregnancy.  
There was also a significant relationship between rheumatic patients and 
unemployment, presumably as this was directly linked to poverty. 
 
It is known that the rheumatic process affects the mitral valve more commonly than 
the aortic, with the tricuspid much less and the pulmonary valve hardly at all (109), 
(110). The pathology of the mitral valve in most cases is that of pure mitral stenosis, 
mitral insufficiency or both, with mitral regurgitation being predominant in the 
young patient but mitral stenosis becoming progressively more common with age 
(104). Aortic stenosis from chronic rheumatic heart disease is typically associated 
with aortic insufficiency. Our study showed almost equal percentages of aortic and 
mitral valve replacements, together forming the bulk of our replacement program. 
Our prostheses of choice in the young rheumatic patient is the mechanical valve 
because of the notion that insertion of mechanical prostheses can avoid the 
reoperation due to degeneration of bioprosthetic valves which almost always will 
occur in the young patient (7). Unfortunately, however, re-operations cannot be 
completely eliminated, due to thrombotic and infective complications of mechanical 
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valves which, if they occur, can be rapidly fatal especially in indigent patients who 
are non-compliant with respect to anticoagulation and easily lost to follow-up. The 
choice is therefore difficult to make in the absence of both short- and long-term 
outcome data.  
An overall rheumatic mitral repair rate of about 8.7% is rather low compared to 25% 
as reported by Yau et al. in a Canadian study (111) and the greater than 50% 
reported in other studies (14). This may not be very surprising with the large number 
of badly damaged and irreparable valves as a result of the rheumatic process. The 
success of mitral valve repair will depend on variable factors including proper 
patient selection and a steep learning curve which ultimately depends on volume of 
suitable cases and therefore development of expertise. There is consensus on the 
advantages of mitral valve repair over replacement in patients with non-ischemic 
mitral valve disease, although in ischemic mitral repair, a lower 30-day mortality did 
not achieve statistical significance (10). Results of repair of rheumatic mitral valves 
remain  inconsistent, as there is a wide spectrum of the disease process as well as 
significant variability in the technical feasibility of repair (112). In our study, there 
was no significant difference in the median time to redo between repair and 
replacement of rheumatic mitral valves although it took twice as long for replaced 
valves to fail. However, although there was a slight advantage of repair over 
replacement in non-rheumatic valves, this was not statistically significant.  
There was a significantly higher proportion of concomitant coronary artery bypass 
grafting with procedures in non-rheumatic patients, as a large proportion of non-
rheumatic cases may be of ischemic etiology. This may explain the slightly longer, 
albeit not statistically significant, time to redo of mitral repairs in non-rheumatics as 
there is revascularization of the valve apparatus. However, other confounding or co-
morbidity factors such as the more advanced age of the non-rheumatic patients may 
eliminate this advantage. Most of the valve repairs were performed by a single 
surgeon, hence eliminating the learning curve and standardizing the surgical 
outcome. Most of the techniques of repair were valvular elongation and sliding 
plasty. All the repairs were supported with ring annuloplasty and assessed with 
intraoperative TEE. There was also better 30-day mortality in repair of rheumatic 
versus non-rheumatic valve. However, there was no observed advantage in ICU 
stay.  
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Repairs avoid the lifelong anticoagulation necessary for mechanical prostheses and 
the degeneration of tissue valves and hence should play a more prominent role in the 
armamentarium of cardiac surgeons, especially in developing economies. Another 
important advantage of mitral repair is the preservation of intrinsic mitral apparatus 
which allows for improvement of post-operative ventricular function. Unfortunately, 
it is more time consuming and requires patience but efforts must be made to develop 
these skills in the next generation of surgeons. Early referral for surgical 
intervention will increase the number of valves amenable for valve repair. This is 
often a difficult decision on the part of the cardiologists and constant interaction of 
physicians and surgeons may reduce the time to surgery. In this study, we did not 
evaluate for long-term follow up. 
The success of mitral valve repair is noticed to be dependent on the mitral valve 
pathology and anatomy though there is no consensus on what anatomy exclusively 
precludes attempt at repair. Therefore, surgeons’ experience will ultimately 
determine what gets repaired or replaced. The development of a ‘scale of distortion’ 
of the mitral valve will be necessary as a guide for those involved in the art of valve 
repair because, often, considerable time and effort is put into the repair attempt, only 
for it to fail ‘on table’ and then a replacement is inevitable.  
The success of mitral valve repair in rheumatic patients is improved significantly 
when aggressive tissue resection is performed to remove all diseased tissue whilst 
leaving behind as much unaffected tissue as possible and using techniques not 
classically described for rheumatic mitral valve repair, such as resuspension of 
leaflets using polytetrafluoroethylene neochordae, use of a tricuspid autograft or a 
mitral homograft (16).  
In the developing world, there is still a place for other techniques of valve ‘repair’ 
that have all but disappeared from the practice in more developed countries. 
Procedures such as closed mitral valvulotomy and commissurotomy which, if 
successful, could delay the insertion of bioprostheses and lifelong anticoagulation, 
especially in the young rheumatic patient. 
In our environment, it is very difficult to conduct research on outcome analysis of 
long term factors for obvious reasons. Many of our patients are indigent and often 
travel great distances for medical attention. For this reason, we have decided to 
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analyze only three early outcome variables, namely ICU stay, hospital stay and 30-
day mortality. Time to reoperation was analyzed as a late outcome for patients with 
available and reliable data. 
 
a. ICU Stay 
 
It has become very important in the field of cardiac surgery to predict the length of 
ICU stay by developing risk scoring systems to determine preoperative mortality 
risks. ICU stay is expensive and personnel consuming, especially in developing 
countries and so this information becomes vital in the preparation of valve surgery 
programs. Unfortunately, many of the existing systems do not allow for variables 
such as etiology of valve lesions, therefore highlighting the need to have a scoring 
system appropriate to our environment where rheumatic disease will continue to 
play an important role. At GSH, the Cardiothoracic ICU is a six bedded unit that 
caters for our immediate post-operative needs. 
Patients with rheumatic valve lesions generally spent significantly less time 
(76.5hours) than non-rheumatics (99.3 hours) in the ICU irrespective of procedure 
performed. The younger average age of the rheumatic patient may have contributed 
to reduce the incidence of co-morbidity, which is more common with the older, non-
rheumatic patients. This may explain the finding of rheumatic mitral valve patients 
having stayed significantly shorter periods in the ICU compared to non-rheumatic 
mitral patients, although this was not observed in the case of aortic procedures. 
It appears that the short-term advantage that repair gives over replacement was 
pronounced in the rheumatic group with repair of rheumatic valves correlating with 
a shorter ICU stay than in the case of replacements (66.9 hours vs 77.5 hours), 
whilst the converse was true in non-rheumatic valves (113.2 hours vs 94 hours). 
This difference was however not statistically significant. It has however been 
proposed that as a result of a perceived progression of the disease process and 
inferior durability of reconstruction, repair of rheumatic valves may become 
redundant in the long-term, despite its short-term advantages. The repair of 
rheumatic valves, though controversial, should however be encouraged whenever 
possible in the developing world, therefore accepting the risk of reoperation (17). In 
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the setting of non-rheumatic mitral valve disease, repair is generally believed to be 
superior to replacement in the long term with better preservation of LV function, 
improved late survival and a lower likelihood of valve-related complications (19).  
However, there is a trend for the average ICU stay of patients who have undergone a 
first procedure to be shorter than that following redo operations  (p=0.08). Patients 
presenting for redo procedures are usually acutely ill and in a worse NYHA class. 
Reoperations are technically more demanding as a result of severe mediastinal and 
pericardial adhesions and often subsequent bleeding from inadvertent lacerations. It 
is no surprise, therefore, that the ICU stay may be more prolonged in these cases. 
The lack of a high dependency unit (HDU) in our hospital also prolongs ICU stay in 
patients who cannot yet be transferred to the regular ward as they still require close 
monitoring. 
Of all the co-morbidities, hypertension (p=0.006), smoking (p=0.037) and obesity 
(p=0.031) significantly increased ICU stay among the non-RHD patients. 
Ventilatory requirements are usually increased in smokers, hence the need to advise 
patients to stop smoking well ahead of their elective surgeries. 
 
b. Hospital Stay 
 
Rheumatic patients generally also had a shorter period in hospital than non-
rheumatics (11.5 days vs 13.8 days; p=0.05) and this was particularly evident in 
mitral procedures, with hospital stay between rheumatic and non-rheumatic aortic 
procedure patients being similar. This may suggest that patient characteristics in 
aortic procedures were similar whether rheumatic or not, whilst being different in 
mitral disease. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 74 
c. 30-day mortality 
 
One of the important outcome variables in cardiac surgery is the 30, 60 or 90-day 
mortality which is defined as ‘all cause’ mortality at 30, 60, or 90 days. This refers 
to all deaths from any cause after a valve intervention.  
This information is especially valuable to cardiologists and surgeons as they discuss 
the possible potential risks and benefits with the intended patient. Even though some 
workers have challenged the usefulness of these figures and have proposed that a 
longer term outcome may be more informative for the discerning patient (20), it 
nevertheless continues to remain a very useful tool. We decided to utilize the 30-day 
mortality figures as this would be the most reliable in patients who are prone to poor 
follow-up compliance. Edwards et al. (5) also found that 30-day mortality correlated 
well with 1 year mortality figures after valve replacement.  
Patients with no or minimal symptoms (NYHA Class I &II) tend to do very well 
after heart surgery while the results in patients in advanced NYHA classes show 
excessive morbidity and mortality. This has led to the recommendation to perform 
surgery at an earlier stage of the disease process. Unfortunately, the majority of our 
patients still present in advanced NYHA Class III. 
The overall 30-day mortality rate in the non-rheumatic patients was 10.6% (72) and 
2% (15) in the rheumatic patients. This significant difference was likely the 
contribution of the older, sicker, patients in the non-rheumatic group. The overall 
30-day mortality rate for the primary operation was 3.7% compared to 7.9% for the 
first reoperation. This compares favorably with other centers in developing countries 
(56) where the 30-day mortality of redo procedures is about double the mortality of 
first procedures. Although our study did not particularly investigate differences, if 
any, between patients having a redo as a result of a failed mechanical or tissue valve, 
it is generally known that bioprosthetic valves usually fail chronically whereas, 
mechanical valves instead fail acutely and with a higher mortality. The 30-day 
mortality figures following valve repair or replacement in rheumatic patients were 
not statistically different in our analysis, and a similar observation was seen in non-
rheumatic patients. However, there was a trend towards lower mortality in repairs 
than in replacement of rheumatic valves, while a reversed trend of lower mortality 
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following replacement was seen in non-rheumatic patients. Rheumatic patients had 
better 30-day mortality rates of repair (0%) than in non-rheumatic patients (14%) 
and a similar advantage in replacement (2.14%) compared with 9.45% in non 
rheumatics. The younger, rheumatic patient with less co-morbidities will have a 
better chance of survival following these procedures.  
The same co-morbidities that were significantly associated with ICU stay were also 
noted to increase 30-day mortality, namely hypertension (p=0.001), smoking 
(p<0.0001) and obesity (p=0.049). Ischemic heart disease (p=0.004) was an 
additional risk factor associated with early mortality. Clearly, there is a need to 
address these factors to mitigate the incidence of early mortality. 
 
d. Time to Re-operation 
 
There is always a risk of reoperation no matter the type of prosthesis. Unfortunately, 
no single prosthesis type has completely eliminated this risk. Though the reasons 
and pattern of failure differ, reoperation is necessary when the patient outlives his 
valve. Consequently, the younger the patient, the more likely the chances of a 
possible re-replacement. With a background of rheumatic disease, returning patients 
with failing mechanical valves did so much earlier in our series compared to tissue 
valves (4.3 years vs. 9.6 years; p<0.0001). 
The most common reason for failure of mechanical valves was acute thrombosis 
usually as a result of poor anticoagulation. This is contrary to what occurs in Ghana 
where strict anticoagulation control has almost completely addressed this mode of 
failure to the extent that mechanical valves are used exclusively with very good 
results. Tissue valves are hardly used, for example, in the Cardiothoracic Centre in 
Accra – personal communication (113).  
The intention of implanting mechanical valves is the benefit of longevity and 
avoidance of a redo operation. With the median time to redo of the mechanical 
prosthesis is this study cohort of about 4 years and 9.6 years for tissue valves, this 
objective has clearly not been realized. These figures are only representative of the 
patients who returned for a reoperation at our center and it is possible that there may 
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be others who failed acutely and presented at other centers in the country or died 
before reaching hospital. 
Is the mechanical prosthesis therefore more of a ‘disease’ than a ‘cure’ in limited 
resource countries? 
Other studies will need to look into anticoagulation monitoring, especially in this 
environment, as this may hold the answers to the reason of the failure of these 
valves. 
Our results suggest that it may be more expedient to insert tissue valves which will 
ultimately fail but in a more predictable way, therefore making it a priority to 
conduct research geared towards improving the longevity of tissue valves currently 
in use. 
Until then, concerted efforts at proper patient anticoagulation education and follow-
up, provision of INR facilities in rural areas and better coordination of heart valve 
services in referral hospitals in South Africa may reduce the incidence of acutely 
obstructed mechanical valves. 
We also therefore need to overcome the mindset of fear of re-operations, because re-
operations become inevitable whether a tissue or mechanical valve is implanted in 
our environment as most of our patients will outlive their prosthesis.  
Time to re-operation of rheumatic mitral valves that have been repaired (3.4 years), 
is shorter but not significantly so from those that were replaced (6.3 years). This is 
disappointing in our setting, because repair whenever possible, will obviate the need 
for anticoagulation and avoid the catastrophes thereof.   
Our analysis showed that time to re-operation was only significantly different 
between rheumatic and non-rheumatic patients in the 40-50 year age group 
(p=0.0185). This appears therefore to be the age group around which prospective 
studies could be designed to understand the differences in outcome between 
rheumatic and non-rheumatic patients. 
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CHAPTER  6.  CONCLUSIONS 
 
Valve replacement continues to occupy a large proportion of our cardiac surgical 
workload at the GSH, primarily because of the huge burden of rheumatic heart 
disease whose incidence in South Africa appears unabated. 
In order to stem the potential of prosthesis-related disasters, the traditional practice 
of inserting mechanical prostheses in young rheumatic patients is challenged by the 
lack of evidence of mechanical valve longevity shown in this study. 
 While progression of the rheumatic process and prosthetic valve thrombus were 
responsible for the majority of re-operations, it is virtually impossible to halt the 
chronic rheumatic process with other valve sites subsequently succumbing to the 
destructive process. Although technically, this is not a ‘failed’ prosthetic valve, the 
patient is subjected to a re-operation for a valve procedure at another site. On the 
other hand, rigorous INR control policies including better patient follow-up, 
availability of self-test INR kits and fixed Warfarin dosing regimes may reduce the 
risk of prosthetic valve thrombosis that will occur with sub-therapeutic Warfarin 
doses.  
A more aggressive approach to valve repair needs to be adopted as repair rates are 
still low. This may entail earlier referrals for surgery, before the valves become 
irreparably damaged as well as overcoming the steep learning curve for these 
difficult procedures. Furthermore, research geared towards improving the durability 
of bioprosthestic valves should continue to be encouraged.  
Prospective studies in the 40-50 year age bracket of patients is needed, since this 
was the only group where mechanical valves failed significantly earlier in the 
rheumatic patient compared to the non-rheumatic patient (5.3 versus 7.4 years; 
p=0.018). This may better facilitate an understanding of the reasons leading to 
prosthetic valve failure. 
South Africa is a dynamic environment where major social changes have occurred in 
the last two decades. As was noted earlier, rheumatic heart disease is distanced from 
its early beginnings as rheumatic fever by a gap of 10 to 15 years, and it may come 
as no surprise that analysis of the now improved social demographics such as 
housing and employment belie the contribution of a lifelong history of poverty. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 78 
Conversely, though, once an individual has missed a chance at education, this may 
not be so easily undone, even though he or she now lives in a better house. 
There remains, however, a higher percentage of informally housed patients in the 
RHD group compared to non-RHD one and, although there are reasonably high 
percentages of formal housing and employment in this same group of patients, these 
numbers are significantly lower than is the case in the non-RHD patients. It is 
important to realize that this is what has been specifically compared. The analysis 
has not compared, for example, formal versus informal housing in the context of 
RHD alone, but rather informal housing amongst RHD patients versus informal 
housing in non-RHD ones. 
The observation that mechanical valves appear to ‘fail’ earlier than tissue valves 
clearly does not follow what is known about mechanical valves in first world 
countries. However, this is exactly the point that needs to be emphasized here. Could 
it be that the ‘right’ valve is being placed in the ‘wrong’ patient? Mechanical valves 
need more rigorous follow-up than tissue valves. Could the low standard of 
education of our patients affect their understanding of the requisites for mechanical 
valves, that is anticoagulant drug compliance? The problem therefore lies clearly 
with the patient, or does it? Could the problem be one of apathy related to the 
expectations these patients have in a country where social equality is only now 
undergoing positive change, but where crime fueled by problems of unemployment 
and drug abuse is rife? Is it simply a problem related to access to clinics for routine 
INR tests? Could new anticoagulants such as Dabigatran, which requires less 
frequent INR testing, improve the outcome following replacement of diseased 
valves with mechanical prostheses? Could it be that we are not doing enough in 
terms of follow-up? 
Perhaps all of these hold a modicum of truth. A more definitive answer will 
certainly require carefully controlled prospective studies and, of course, time. 
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November 17, 2011 
 
Professor Risenga Frank Chauke 
Department of Cardiothoracic Surgery 
University of Limpopo-Medunsa campus 
Ga-Rankuwa, Tshwane 
 
 
Dear Professor Chauke 
 
Response to Thesis Review of Dr Akinwumi Ogunrombi 
 
Thank you for your thorough review of Dr Ogunrombi’s thesis entitled “Sixteen Year 
Retrospective Analysis of Rheumatic and Non-Rheumatic Heart Disease Patients 
Undergoing Valve Procedures at Groote Schuur Hospital: First Incidence Single Aortic 
and Mitral Valve Replacement”. 
 
Dr Ogunrombi has hopefully addressed your questions satisfactorily and I include a 
summary of his changes below. Additional to this are the mostly typographical changes 
required by the second reviewer. 
 
While both Dr Ogunrombi and myself appreciate the limitations of a retrospective study, that 
is, in terms of demonstrating at most an association between a variety of risk factors and 
eventual outcome, he had, I believe, recognised this shortcoming and not hidden that from 
view. He is a co-author on a subsequent study which addressed the problem more precisely 
by performing propensity matching between cohorts of mitral valve repair and replacement 
patients, thereby controlling for extraneous variables. This was in my mind beyond the scope 
of this Masters degree study but I also believe he has performed a valuable and long overdue 
analysis of the outcomes of indigent rheumatic patients undergoing valve surgery, thereby 
paving the way for more definitive studies. 
 
 
Yours sincerely 
 
 
 
 
 
Dr PAUL HUMAN
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 2 
 
SUMMARY OF CHANGES 
 
CHAPTER 1 
 
1 Source of figures and tables: These have now been appropriately acknowledged. 
2 Formatting in bold/regular: This has now been corrected throughout 
3 Discussion under valve pathology: This has been added and the text under “Aortic 
Valve” which was misplaced has been moved to “Mitral Valve”. 
 
CHAPTER 2 
 
1 Source of figures and tables: These have now been appropriately acknowledged. 
2 Spacing on p17 corrected 
3 Style of writing: made same for tables and figures 
4 Reference 35 in bold: made regular 
5 Figure 5: The legend which refers to survival is a reference embedded in the figure in 
the original publication. The chart correctly indicates numbers of patients across the age 
groups. 
6 References 15/16 incorrect: This has been corrected. 
 
CHAPTER 3 
 
1 No discussion on methods: I would agree that, for a prospective study, methods 
pertaining to the surgical aspect of such a study would need to be included. Since this is 
a retrospective study, the methodology refers purely to the statistical analysis 
performed. I believe that Dr Ogunrombi has discussed the cohort of patients in 
reasonable detail and indeed the challenges of the study, as well as the statistical 
methods used. 
2 Core data/data crucial to analysis: An improved definition of these terms has been 
provided: 
“Even in the original Summit database, demographic and comorbidity data or type of 
valve implanted, for example, was incomplete although core data, that is relating to the 
etiology, the surgical procedure performed and short-term outcome, were nevertheless 
available. In some cases though, patients operated from 1993 but prior to 2003 (the 
capture period for the Summit database) were excluded from the study when even these 
core parameters were unavailable.” 
3 How many of 1449 patients excluded? What are host of confounding factors? Were 
patients with “impure” data included?: The confusion in this regard was due to  
typographical errors in Table 6 (now Table 7) as well as the lack of a definition of what 
was meant by the above mentioned terms. All of the 1449 patients were in fact included 
in the study (see next point). 
 
CHAPTER 4 
 
1&2 TABLE 6 (Now Table 7): The numbers of patients receiving either a mechanical or 
tissue valve was reported in error in this table, although the relative percentages given 
were correct. The numbers have been corrected to 458 and 176 respectively for RHD 
patients and 209 and 251 for Non-RHD patients. A footnote has also been added to the 
table indicating that these figures were dependent on availability of data since, in 136 
RHD patients (10.7%) undergoing replacement and in 219 Non-RHD patients (9.4%) 
undergoing replacement, this information was not available. The total number of 
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repaired plus replaced RHD patients is 770 and the total number of repaired plus 
replaced Non-RHD patients is 679. Together these make up the 1,449 patients of the 
cohort. 
3 Reoperation breakdown: This has now been included as Table 6. 
4 IHD not included in Table 5, but included in Table 6: IHD has now been included in 
Table 5 and as “Simultaneous CABG” in Table 7 (previously Table 6). 
5 Other co-morbidity factors in Table 7: Hypertension, diabetes, smoking, obesity and 
IHD have now been included in Table 8 (previously Table 7). Additional comments  
have been added in this regard in Chapter 5. 
 
CHAPTER 5 
 
1&2 We agree that the findings are controversial but most of what is known relates to First 
World scenarios. The problems of compliance, both in terms of performing regular INR 
tests and with respect to taking anticoagulative drugs, may well be appreciably large in 
an indigent, albeit urban, population and Dr Ogunrombi has added discussion on this as 
well as the social dynamics and its potential impact in a country such as ours. 
You are correct that much of the discussion is based on assumption.  Unfortunately, 
such a study, as is the case with most retrospective studies, serves little purpose other 
than to identify potential hypotheses where causation needs to be unambiguously 
tested. Again, this was outside the scope of the thesis for practical reasons. 
Nevertheless, I feel that Dr Ogunrombi has extracted as much as was possible from the 
available data and gained significant insight and understanding which would assist him 
immeasurably in future research in this field. 
3&4 In Chapter 6, Dr Ogunrombi has added commentary (again an assumption) 
hypothesizing the disparity between education and housing and why improvement in 
the one does not immediately imply the other. 
5 Is the valve the problem or the patient?: Dr Ogunrombi has added thoughts on this in 
Chapter 6. 
6 Table 8 (previously Table 7) now includes a breakdown of valve, prosthesis type and 
repairs. 
7 Reoperation surgery adds a further dimension of complexity since this could refer to 
reoperation of the same valve or of the patient, where alternative valves are 
compromised. Also, sometimes, an original tissue bioprosthesis could of course be 
replaced with a mechanical prosthesis. Whereas I agree that an analysis of reoperations 
would be of particular interest, our restriction of Dr Ogunrombi’s study to single valve, 
first time procedures avoided these complexities in an already variable-rich data set. 
 
CHAPTER 6 
 
1-3 These points are now briefly discussed. 
 
